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ABSTRACT
It has been shown that impaired preoperative nutritional status
and the hyperbilirubinaemia of biliary obstruction are associated and
are of prognostic importance following surgery. This study examined
the relationship between hepatic glucose production and muscle
catabolism as demonstrated by the 'Glucose-Alanine Cycle' to assess
the nutritional importance of this cycle in patients with biliary
obstruction. Twenty three patients were studied, 10 with normal liver
function and 13 with obstructive jaundice. All patients were
suffering from gastrointestinal or intra-abdominal malignancy. Fasted
patients were challenged with an intravenous bolus of alanine and
glucose on separate days, both before and after surgery. Nutritional
status was comprehensively assessed before each test. No
abnormalities in either glucose or alanine metabolism was found which
could be associated with the presence ' of biliary obstruction. No
association could be found between variations in nutritional status
and alanine or glucose metabolism. Prior to surgery, maximal
nutritional support was offered by the method most appropriate to each
patient. The postoperative return of serum bilirubin levels towards
normal was accompanied by no demonstrable alteration to glucose or
alanine metabolism. This study was unable to demonstrate any
abnormality in the dynamic equilibrium of the glucose alanine cycle
which could be associated with poor nutritional status or biliary
obstruction, both of which are related to postoperative prognosis. It
does not indicate any method for augmenting routine nutritional
support which in turn might improve the postoperative prognosis in





The importance of nutritonal status in the patient with biliary
obstruction has been documented by earlier workers in this department
(Allison et al 1979, Halliday et al 1982, 1985). On the basis of
results from these and other studies (Braasch and Gray 1977, Warren et
al 1975) a link between poor nutritional status, the severity of
biliary obstruction and high postoperative morbidity and mortality
rates is now well established. However, trying to assess the value of
nutritional support, particularly in the preoperative period, is
difficult.
The increased surgical risk encountered by the patient with
obstructive jaundice is multifactorial in nature. In addition to
nutritional status being an important prognostic factor (Allison et al
1979, Warren et al 1975) duration and depth of jaundice are important
as are related pathologies such as malignancy or the development of
renal failure. The question to be answered by this study was, 'Can
standard methods of nutritional support be altered or augmented to
improve the postoperative prognosis for patients with obstructive
jaundice'.
The indications for and value of nutritional support in disease
can be studied in three different ways. The first 2 methods are aimed
at demonstrating the value, or potential value, of aggressive
nutritional support. In the first, indices of nutritional status can
be recorded before and after a period of nutritional support. Many
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have anticipated that a demonstrable improvement in these indices
could be expected to be rewarded by an improved postoperative
recovery.
A second method of study, often combined with the first, involves
the recording of postoperative morbidity and mortality rates in a
group of randomized patients, some of whom have received nutritional
support the remainder receiving no additional nourishment. For
statistical significance to be achieved in such studies the number of
patients admitted to the study would need to exceed 100. Indeed in a
recent report (Muller et al 1982) where preoperative feeding in 160
patients was studied a claimed significant reduction in the
postoperative morbidity rate was incorrect on re-analysis of the data
presented, and the addition of one extra death to the pre-operatively
fed group also abolished the significance of the mortality rate.
Therefore, even a carefully controlled study involving large numbers
of patients fails to provide convincing evidence of the value of
preoperative intravenous nutrition over an extended period.
A third approach was suggested for this study. Abnormalities in
metabolism at a cellular level might provide the reasons for the
particular nutritional deficiences seen in patients with biliary
obstruction. The 'Glucose-Alanine Cycle' has been used recently to
provide an explanation for nutritional irregularities in septic
postoperative patients (Royle and Kettlewell 1981). Since the main
organs involved in this cycle are the liver parenchyma and peripheral
muscle, it was felt that this would be a useful metabolic process to
study in biliary obstruction.
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Although abnormalities in the glucose alanine cycle had been
previously demonstrated only in parenchymal liver damage, the links
already described between biliary obstruction and nutritional deficit
were considered sufficiently strong to warrant investigation of this
metabolic cycle in obstructive jaundice.
The aim of this study, therefore, was to examine the glucose
alanine cycle in an attempt to identify an abnormality specific to
biliary obstruction which might suggest appropriate therapeutic
counter measures.
Although poor nutritional status is an important prognostic
factor in obstructive jaundice (Halliday et al 1982, 1985) two
mechanisms may account for this. Muscle wasting and weight loss may
be a reflection of the nature of the pathology, (e.g. sepsis from
chronic intermittent cholangitis in relation to a ductal calculus or
benign stricture), or increased protein turnover, (e.g. a wasting
disease like carcinoma of the pancreas). Poor nutritional status in
such patients would become an additional burden in the post-operative
period as it would in a non-jaundiced patient. Alternatively, the
patient with obstructive jaundice might experience an abnormal
metabolic drive, resulting in an inappropriate manipulation of
endogenous fat, glycogen or protein stores, or an abnormal
assimilation of an enteral or parenteral diet. Abnormal fat
absorption is well recognized in obstructive jaundice due to the
absence of bile salts from the small bowel, and the loss of the
entero-hepatic circulation.
The aminoacid alanine is the major protein-derived substrate for
hepatic gluconeogenesis. An abnormality in alanine metabolism might
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indicate an altered rate of muscle catabolism, or hepatic function, or
both. It was the purpose of this study to determine whether patients
with obstructive jaundice experienced abnormalities in alanine
metabolism in the presence of normal glucose metabolism in either the
preoperative or postoperative periods. Such abnormalities might
render such individuals more prone to a deterioration in nutritional
status with the resultant increased postoperative morbidity and
mortality rates. If this was confirmed it might indicate the need for
appropriate dietary or metabolic manipulation to improve postoperative
prognosis. The absence of such changes would indicate that the
routine indications for, and techniques of, nutritional support would
need no adaptation for the patient with obstructive jaundice, within
the limits of this study.
The clearance of intravenous loads of alanine and glucose was
examined. Glucose clearance was measured to determine whether this
was normal or abnormal in obstructive jaundice. An abnormal glucose
clearance rate would complicate interpretation of alanine clearance
studies. In order to select a study group likely to have poor
nutritional status only patients with intra-abdominal or
gastro-intestinal malignancy were admitted to the study.
Intravenous glucose clearance was impaired in both study and
control groups to the same extent. As will be seen later many workers
have noted abnormal glucose metabolism associated with malignancy.
The presence of obstructive jaundice did not seem to influence this.
This is an important finding, as abnormal liver function has also been
shown to cause alterations in glucose metabolism.
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In addition, it was found that alanine clearance was the same in
both groups preoperatively, although there was an implication that
those jaundiced patients with clearance rates at the lower end of the
range had improved clearance after surgery when liver function had
begun to recover.
However, it would appear that obstructive jaundice does not
influence the dynamic equilibrium of the glucose-alanine cycle.
Equally important was the similarity found in fasting levels of both
alanine and glucose in the study and control groups. It implied that
the metabolically stable, fasted patient, displayed a glucose and
alanine homeostasis unaltered by the presence of obstructive
jaundice. Although these are the results of major importance in this
study, futher data analysis produced findings of interest which are
detailed later.
Glucose metabolism and maintenance of a normal equilibrium in the
related processes of hepatic glueoneogenesis and muscle catabolism,
appear to be governed by homeostatic mechanisms easily capable of
overcoming the abnormal metabolic stresses found in the patient with
obstructive jaundice. This suggests that the rate of deterioration in
nutritional status in patients with obstructive jaundice may be no
worse than would be found in similar pathology in the non-jaundiced
patient.
This work represents a rudimentary investigation into amino acid
metabolism in the patient with obstructive jaundice in an attempt to
determine the role of preoperative nutritional support. There is no
evidence from this study to suggest that anything other than orthodox
preoperative nutritional support is needed in the patient with
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obstructive jaundice. However, other results suggest there may be an
indication to prolong or intensify the nutritional support offered
postoperatively.
Introduction
"It takes a great deal of history




2.1.1 Nutrition and the patient with obstructive jaundice
Definitive management of biliary obstruction often presents a
major surgical challenge. That it is fraught with high morbidity and
mortality rates may have as much to do with abnormal hepatic
metabolism as with the complexity of the surgery. Many reports exist
of the complication and death rates following such surgery (Braasch
and Gray 1977, Warren et al 1975, Fish and Cleveland 1964, Hicks and
Brooks 1971, Monge et al 1964, Pliam and Re Mine 1975). Suggested
prognostic factors include operative technique, (Hicks and Brooks
1971), attention to blood volume and electrolyte balance (Warren et al
1975), and preoperative biliary drainage (Braasch and Gray 1977, Fish
and Cleveland 1964). In addition, the degree of impairment of hepatic
function is important. The postoperative complication rate appears to
be directly proportional to the preoperative depth of jaundice and
preoperative hypoproteinaemia (Braasch and Gray 1977, Fish and
Cleveland 1964). In particular hypoalbuminaemia, and a prolonged
prothrombin time and poor nutritional status are important prognostic
factors (Braasch and Gray 1977, Warren et al 1975, Allison et al
1979).
In the patient receiving surgery for obstructive jaundice,
therefore, a combination of meticulous operative and perioperative
care, and attention to the metabolic capacity of the liver may reduce
to a minimum the postoperative complications (Braasch and Gray 1977).
Simple metabolic tests have been used in such patients, in the past,to
identify impaired metabolism. Antipyrine clearance (MacPherson et al
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1981, Vessell 1979) provides an indirect measure of cytochrome p450
activity in hepatocytes.
The present study was designed to investigate whether the
association between impaired preoperative nutritional status and the
high morbidity and mortality rates found after surgery for biliary
obstruction could be better understood by examining the dynamics of
the glucose alanine cycle.
2.1.2 The relevance of nutrition to surgery
In a series of elegant studies on the traumatised patient
Cuthbertson (1929, 1930, 1931, 1932) recorded the alterations in body
composition, including loss of fat and protein mass, in response to
trauma. In addition, he recorded the beneficial effect of a high
protein, high calorie diet in halting or reversing this trend
(Cuthbertson 1936). In patients receiving surgery for peptic ulcer,
Studley (1936) noted a postoperative mortality rate of 33 percent in
those who had lost more than 20 percent of their normal body weight.
This compared to 3.5 percent in patients with more modest weight
loss. Lawson in 1965 examined a group of surgical patients with
severe postoperative complications. He concluded that patients who had
lost 30 percent of their normal weight at surgery were unlikely to
survive. All 8 patients in his study with this degree of weight loss
died.
Although the early studies of Studley and Cuthbertson
demonstrated an association between poor nutritional status and
increased postperative morbidity and mortality rates, an association
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between preoperative intravenous nutrition and an improvement in these
statistics has been more difficult to demonstrate. Russell and
Jeejeebhoy (1983) and Baker et al (1982) have suggested that in
suitably controlled prospective studies, the changes in nutritional
status are too subtle for accurate measurement and that clinical
judgement can be equally useful. Indeed, only two studies (Heatley et
al 1979, Muller et al 1982) have suggested preoperative parenteral
nutritional support may reduce postoperative complications and
sepsis. The most convincing of these (Muller et al 1982) involved
studying 125 patients and assessing the value of 2 weeks of
preoperative intravenous feeding. A significant reduction in
morbidity and mortality rates was reported in the nourished group.
However, re-analysis of their morbidity results, using their reported
data and the Chi-squared test for significance, demonstrated no
siginificant difference between the groups. This was in direct
contradiction to the reported results. The addition of one extra
death to the mortality group also abolished the statistical
significance of this figure. Both statistics had been reported
significant for p < 0.05 on the Chi-Squared test. Koretz (1984) notes
in a personal communication from J Muller that the study was begun
with 3 cohorts one of which was subsequently excluded. No statistical
correction was made for the inevitable bias produced by this.
Fifteen other studies have been conducted to investigate the
value of preoperative and perioperative nutritional support. The
pathologies under study include gastrointestinal cancer (Holter and
Fischer 1977, Thompson et al 1981), upper gastrointestinal cancer
(Moghissi et al 1977, Simms et al 1980, Schildt et al 1981, Lim et al
1981, Moghissi et al 1982), colorectal surgery (Collins et al 1978,
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Preshaw et al 1979, Jensen 1982), cystectomy (Hensle 1978, Simms and
Smith 1981), ear, nose and throat cancer (Sako 1981), surgery for
valvular heart disease, (Abel et al 1976), and abdominal surgery
(Garden et al 1983). In none of these studies is there a reduction in
either morbidity or mortality rates associated with nutritional
support.
Heatley et al 1979 demonstrated that preoperative intravenous
feeding reduced the rate of wound infections in patients having
surgery for upper gastrointestinal malignancy. Therefore of the two
studies existing to suggest that preoperative intravenous nutrition
has any value in reducing surgical complications, only one has been
correctly reported. The success of the second study may be partly due
to patient selection. Patients with upper gastrointestinal malignancy
often present with progressive dysphagia. Therefore the weight loss
they display is in part due to mechanical problems making food
ingestion difficult. It can be argued that this special situation is
more likely to respond to intravenous support than other pathologies
with associated weight loss where there was no mechanical interference
with oral intake.
Although such studies assess the important clinical parameters of
morbidity and mortality, and the value of preoperative nutrition, two
major problems arise. To obtain valid and useful data large numbers
of patients are required, and a homogenous patient population with
similar nutritional problems is difficult to obtain. Often combined
with this type of study an alteration in a variety of sensitive
indicators of nutritional status can be assumed to be of prognostic
importance during a period of careful nutritional support. However,
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there is still no universal agreement as to the most useful
anthropometric and biochemical tests for this type of measurement and
relatively large numbers of subjects are still required.
An alternative to these types of study, which has been widely
practised, examines metabolic parameters in different disease states
to discover abnormalities related to nutritional status which might be
correctable with appropriate enteral or parenteral support. The study
described here used this method to assess complementary aspects of
glucose metabolism in the patient with biliary obstruction. All
patients examined were suffering from some form of malignant disease.
Such a group was selected as it was thought they would be more likely
to demonstrate a significant reduction in nutritional status, thus
maximally stressing the metabolic cycles under study.
Metabolic studies have been employed in many different disease
states to allow appropriate prescribing of nutritional solutions for
optimum effect. In respiratory failure careful studies have
demonstrated the value of lipid emulsion in improving the respiratory
quotient, helping to maintain adequate surfactant content of the
alveoli and reducing the fluid load in the circulation.
In hepatic failure it has been noted that there is an alteration
to the normal serum amino acid profile, with a relative increase in
the concentration of the aromatic amino acids (AAA) and a decrease in
the relative concentration of branched chain amino acids (BCAA). This
finding has given rise to the theory that the administration of BCAA
in preference to AAA may correct the abnormality and be of therapeutic
value in this condition.
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Although many studies have been carried out to assess the value
of BCAA in liver disease, only 6 of these employed a control group.
Egberts et al (1981) studied 30 patients without clinically detectable
encephalopathy and noted improved results on psychometric testing of
those receiving BCAA. Fiaccadori et al (1980), in a similar study,
showed no improvement in encephalopathy with the use of BCAA. In the
remaining reports Michel et al (1980) showed no difference between
treatment groups, Rossi-Fanelli et al (1982) demonstrated an
arithmetic improvement in encephalopathy with no clinical advantage in
the BCAA treated group and Cerra et al (1982) showed an improved
outcome with the use of BCAA. This finding is in conflict with that
of Hagenfeldt et al (1981) in a similar study. There is, therefore,
no good evidence to support the routine use of BCAA in patients with
severe liver disease.
It was thought, therefore, that a study of a metabolic pathway
which involved both muscle metabolism and hepatic function could be a
useful tool to determine the effect of biliary obstruction upon
nutritional status. For this reason the glucose-alanine cycle (Felig
1973) was investigated.
2.2.1 The glucose alanine cycle
In the surgical patient the main aims of nutritional support are
to maintain or increase body mass, in particular protein mass, and to
offer sufficient nutrients to produce a reduction in the rate of




















Fig. 1. The Glucose Alanine Cycle
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A variety of techniques are available to assess such nutritional
status, and most of them measure some some aspect of muscle mass
(Bistrian 1981). Peripheral muscle is rapidly catabolised to provide
glucose for energy and aminoacids for tissue regeneration and
maintenance of immunological competence. Increased muscle catabolism
is due to increased energy requirements associated with stress or
trauma (Cuthbertson 1930). One of the important metabolic indices of
protein catabolism is the rate of alanine release from muscle.
Alanine is the principle amino acid produced following muscle
catabolism (Felig 1973), the liver being the principle site for
alanine clearance.
Unlike carbohydrate and fat, no storage organ exists for
protein. All the protein in the body is constantly available for
use. It is present as enzymes, contractile protein and structural
protein. Excess dietary protein is deaminated, urea being excreted
and the carbon framework stored as fat or glycogen.
Cuthbertson (1930) recognised the negative nitrogen balance,
increased urinary loss of urea and decreased intake of food associated
with injury. Liver glycogen stores are normally exhausted within 24 -
36 hours of fasting (Woolfson 1979) . In the patient stressed with
injury or sepsis this glycogenolysis occurs more rapidly. The need
for glucose, however, continues. The brain is an obligatory consumer
of glucose in the early stages of a fast. Although the central
nervous system can eventually adapt to use ketone bodies as an
alternative energy source, initially glucose must be available. Once
glycogen stores are exhausted, glucose is formed from peripheral
protein via the pathways of gluconeogenesis.
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This process accounts for the majority of muscle wasting in the
first days of an otherwise uncomplicated fast. The main products of
muscle catabolism are the aminoacids alanine and glutamate. Of these,
alanine is the principle gluconeogenic aminoacid being converted to
glucose and urea in the liver.
The role of alanine in muscle metabolism and gluconeogenesis was
summarised by Felig (1973), (Fig. 1). In a variety of physiological
and pathological states, studies of muscle derived alanine and hepatic
glugoneogenesis have confirmed the importance of this amino acid (Elia
et al 1980, Royle and Kettlewell 1981).
In muscle, pyruvate is transaminated into alanine. The nitrogen
radicals which are necessary for this transamination are either
products of muscle catabolism or the metabolism of excess dietary
aminoacids. The alanine released from muscle, therefore, acts as a
carrier molecule for nitrogen radicals and for the carbon skeleton
necessary for glucose formation. In the hepatocyte alanine is
deaminated, the nitrogen radical converted to urea or transaminated
into another amino acid, and the carbon skeleton is converted to
glucose. The glucose and amino acids are once more transported to the
periphery where the cycle starts once more.
In the fasted individual there is a net release of amino acids
from muscle. This was first noted by Van Slyke in 1913 in studies on
fasted dogs. The amino acid flux across forearm muscle in the fasted
human was studied by London (1965). He recorded that alanine
accounted for more than 30 percent of the amino acid released.
However, Kominz (1954) noted that alanine accounts for no more than 10
percent of the amino acid residues in skeletal and cardiac muscle.
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Therefore there must be a net synthesis of alanine in the muscle in
the fasted state. The vast majority of peripheral alanine production
arises from the coupling of the carbon skeleton of pyruvate with the
nitrogen radicals of the branched chain amino acids valine, leucine
and isoleucine.
Many amino acids can be converted to glucose in the liver, but
maximal rates for the process are reached for most amino acids at
levels 3 times greater than normal. Maximal gluconeogenic rates for
alanine, however, are not reached until the blood concentration is at
least 20 times normal (Mallette et al 1969).
It would appear, therefore, that a severe impairment of liver
function would be required before alanine clearance would be
affected. Such a change is an unlikely sequel to biliary
obstruction. However, the association between nutritional status and
postoperative prognosis in patients with biliary obstruction is well
proven (Allison et al 1979, Halliday et al 1982, 1985). The aim of
this study was to determine whether the relationship between biliary
obstruction and nutritional status could be elucidated with an
examination of alanine release from muscle and its clearance in the
liver.
Several hypotheses can be proposed. If muscle catabolism is
increased in the patient with obstructive jaundice this may be
reflected in an increased output of alanine from muscle.
Alternatively, an impaired rate of hepatic gluconeogenesis resulting
in a reduced or inappropriate muscle protein turnover may reduce the
available nitrogen radicals and aminoacids for wound healing and
protein reconstruction. Although several workers have shown
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abnormalities in this metabolic cycle in a variety of disease states
(Elia et al 1980, Royle and Kettlewell 1981), the sensitivity of the
methods used and the fundamental relationship between alanine
metabolism and nutritional status have yet to be defined.
In the fasted patient ketone bodies appear to limit alanine
release from muscle once lipolysis is induced (Royle and Kettlewell
1981). If the blood alanine level rises, however, this inhibits
ketone production and the control of muscle catabolism is lost. A
failure of alanine clearance might produce such a reaction leading to
an increase in muscle catabolism and a subsequent deterioration in
nutritional status. However, as already mentioned, except perhaps for
terminal, life-threatening stages of biliary obstruction, such a
deterioration in liver function is difficult to envisage.
The present study was designed to provide preliminary data in
order to help answer these questions. Measuring fasting levels of
alanine in patients with obstructive jaundice would offer some
evidence of the rate of muscle catabolism. The clearance rate of
exogenously administered alanine would determine the integrity of the
glucose alanine cycle.
2.2.2 The alanine clearance study
A single measurement of blood alanine in a fasted individual,
while offering some indication of the rate of protein breakdown, might
be misinterpreted if there was altered hepatic alanine metabolism.
The addition of an alanine clearance study would indicate whether the
gluconeogenic capacity of the liver had been impaired.
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This technique was first used by Felig et al (1969a) when he
administered amino acids to fed and fasting subjects. The
administration of lOg of alanine or lOg glycine was followed by
repeated blood sampling for glucose estimation. No alteration to
plasma glucose was noted after administration of either amino acid in
fed individuals. After an overnight fast, however, the same
individuals demonstrated a marked rise in plasma glucose in response
to the alanine load but not to glycine. This is an energy requiring
process, since none of the glucose formed is used to fuel the
process. Fatty acid oxidation is the principal energy source (Cahill
1970).
The measurment of fasting blood alanine levels in different
physiological and pathological conditions can offer only limited
information about protein catabolism and the rate of gluconeogenesis.
In order to determine the controlling mechanism in gluconeogenesis,
and the prevailing flux in the dynamic equilibrium between glucose and
alanine, an examination of the rate of hepatic clearance of alanine is
required (Elia et al 1980, Royle and Kettlewell 1981). This can
indicate whether an alteration in fasting alanine levels is due to
hepatic alanine clearance or the release of alanine from the
periphery. If normal clearance rates exist the implication would be
that any alteration in fasting alanine levels resulted from altered
peripheral release.
Since the recognition of the role of alanine in glucose
metabolism (Felig 1973) a few workers have employed this dynamic test
of hepatic function to help clarify the equilibrium between glucose
and alanine in different situations. In order to better understand
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the roles of glucagon and insuln in gluconeogenesis, Muller et al
(1971) studied the effect of a constant infusion of alanine on fasted
and fed mongrel dogs. He concluded that in the fasted state an
alanine infusion would cause a rise in plasma glucagon with only a
minimal change in insulin concentration. In the fed state, however,
when exogenous glucose was available the effect of alanine on these
hormones was reversed, the insulin level increasing and the glucagon
level remaining unchanged.
In 1974 Fernandes and Blom used alanine clearance studies to
investigate inborn errors of carbohydrate metabolism in a group of 8
children. They noted that interpretation of a blood glucose rise
following alanine administration may give misleading information about
the integrity of gluconeogenesis from this amino acid, as
hyperalaninaemia in the fasted individual also promotes
glycogenolysis. This may be mediated through the increase in glucagon
levels noted by Muller et al (1971). These workers did not suggest
the appropriate length of a fast to produce complete depletion of
available glycogen, although this is assumed to be 24 -36 hours.
By 1978 specific commoner pathologies were being investigated
with this test. Royle & Kettlewell (1978, 1981) noted lower alanine
levels in fasted septic patients than in non-septic controls. An
alanine clearance study demonstrated unimpaired hepatic
gluconeogenesis, suggesting that muscle release of alanine had been
reduced in sepsis. It was suggested that a relative hyperketonaemia
in the septic patients might be responsible for this decrease in
muscle alanine release.
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All the patients in the study group had developed sepsis
following surgery. All had fasting ketone levels raised significantly
above those of the control patients which returned to normal on
administration of exogenous alanine. It was suggested that the use of
endogenous fat as a principal energy source, with a net release of
ketone bodies and resultant hyperketonaemia, afforded control of
muscle catabolism and alanine release. That hepatic clearance of
alanine remained unchanged indicated that the altered alanine
metabolism occurred in the muscle.
The rapid drop in blood ketone body level following the
administration of alanine was thought to be mediated through increased
insulin production or some non-hormonal mechanism. Nosandini (1981)
demonstrated a non-hormonal, direct reciprocal feedback inhibition of
alanine on ketone body production. Such a finding is disquieting as
it suggests that in conditions where alanine clearance might be
impaired as may be anticipated in liver disease, the inhibiting effect
of hyperketonaemia might be lost leading to an increased rate of
muscle catabolism and consequently of muscle wasting.
Impaired alanine clearance was noted by Elia et al (1980) in
patients with hepatic cirrhosis. In that study basal blood alanine
and the clearance of an intravenous alanine load was examined in a
variety of situations. The patients studied fell into one of several
groups, healthy males fasted for 4 days, 4 insulin dependent diabetic
patients, 4 patients with hepatic cirrhosis, and 4 patients with
muscular dystrophy. In addition, 6 patients having elective total hip
replacement were studied before surgery, 6 hours after surgery and 5
and 7 days after surgery.
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The fasting blood alanine levels in the surgical, starved and
diabetic patients and those with muscular dystrophy were all below
normal. Despite the similarity in these results the use of the
alanine clearance study demonstrated these findings were due to
different mechanisms.
An increased rate of alanine clearance was found after surgery
and in the diabetic patients, but it was unaltered in fasted healthy
men and appeared to be decreased in cirrhosis, a condition where
fasting alanine levels were found to be normal.
Although the control of alanine metabolism occurs in both muscle
and liver, peripheral muscle would appear to be the most important
site for the control of alanine release (Swaminathan 1981), the
metabolic reserve of the liver far exceeding physiological need
i
(Mallette et al 1969).
Recently another controlling mechanism in gluconeogenesis was
elucidated. Sacca et al (1983) noted the stimulatory effect of
adrenaline on gluconeogenesis from lactate and alanine. Adrenaline
appeared to increase the available substrate and had a negligible
effect on hepatic clearance. There was a suggestion that exogenous
alanine is converted to lactate in the liver and that lactate is a
more important gluconeogenic substrate than alanine.
In summary, the glucose alanine cycle is the major metabolic
pathway for converting amino acids to glucose. The organs involved in
this process are the liver and peripheral muscle. Alanine is released
from muscle both following muscle catabolism and following the
metabolism of excess dietary protein. Although the capacity of the
-37-
liver to clear alanine far exceeds the physiological need, in hepatic
insufficiency it is possible that reduced alanine clearance may alter
the control of alanine release from muscle. The rate of hepatic
gluconeogenesis is therefore of relevance to muscle wasting and
nutritional status in the patient with inadequate dietary intake and
hepatic failure.
A number of controlling mechanisms have so far been identified.
Hyperketonaemia would appear to be the principal inhibitor of muscle
alanine production, and a rise in the blood alanine level causes a
reflex inhibition of ketone production (Royle and Kettlewell 1981).
It follows, therefore, that the induction of hyperalaninaemia in the
absence of increased dietary intake of protein would inhibit ketone
body production. Such a situation could arise in cirrhosis where
reduced alanine clearance has been noted (Elia et al 1980). With the
loss of inhibition of alanine release a further acceleration of
alanine production will occur with a further decrease in ketone body
levels. The presence of an artificial hyperalaninaemia in the patient
with liver disease may act as a potent stimulus to muscle wasting and
impaired nutritional status. If this situation obtained in the
patient with obstructive jaundice it would indicate the need for early
institution of adequate nutritional support. However, patients with
hepatic cirrhosis and impaired clearance of alanine display normal
fasting alanine levels (Elia et al 1980). This suggests that alanine
release is still carefully controlled in this pathology.
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2.3.1 The intravenous glucose clearance study
As already shown glucose metabolism is linked to alanine
metabolism. If alanine metabolism is to be studied in patients with
obstructive jaundice more information must be collected about their
individual rates of glucose clearance. In order to avoid the complex
effects of the hormones released in response to the ingestion of
glucose, an intravenous glucose tolerance test would be the most
appropriate method to study this. However, interpretation of
intravenous glucose clearance has been the subject of much debate in
the past, and this is now reviewed.
Since the liver is a major site for glucose clearance, as well as
glueoncogenesis, studies of glucose metabolism in liver disease would
be inadequate without a glucose tolerance test. Glucose tolerance can
be abnormal in a number of conditions. Included among these are
malnutrition (Smith et al 1975), bed rest (Lipman et al 1970 and
1972), starvation (Genuth 1966, Cahill et al 1966) and sepsis (Gump et
al 1974). Even an individual's diet in the pretest period may be
important. West (1978) noted that a high fat, low carbohydrate diet
immediately before the test may impair glucose tolerance.
Although glucose clearance is influenced by a number of factors,
it is principally the insulin response to a glucose load which will
determine the rate of glucose clearance. However, it has been shown
recently (Elahi et al 1981), in healthy male volunteers, that there
may be a discrepancy between the clearance of an intravenous and oral
glucose load in the same individuals. After oral administration of
glucose the circulatory levels of gastric inhibitory polypeptide (GIP)
-39-
have been noted to increase over similar time courses to the increases
in insulin levels. It was shown that patients whose clearance of an
intravenous glucose load was impaired, when compared to the clearance
of an oral load, had higher basal circulating GIP levels and lower
immunoreactive insulin (IRI) responses to intravenous glucose alone.
In addition, the response of both these hormones to oral glucose was
enhanced, suggesting complementary roles for these two hormones in
glucose homeostasis following ingestion of glucose. Such synergy
would appear to be lost when glucose is administered parenterally.
The interpretation of intravenous glucose clearance would appear
equally complex despite the elimination of gut stimulation (Franckson
et al 1962, Moorehouse et al 1964a&b). However, insulin appears to
play a major role in the clearance of an intravenous glucose infusion
(Samols and Marks 1965).
In summary, therefore, since the mechanisms for clearance of an
oral and intravenous glucose load are complex and incompletely
understood, the examination of glucose clearance in surgical patients
might best be conducted with an intravenous glucose tolerance test as
this would avoid the complications of a gastrointestinal endocrine
response. In addition, since such patients are likely to receive
large quantities of parenteral glucose, as part of their management
during a period of nutritional support, the clearance of parenteral
glucose is of practical importance.
Both intravenous and oral glucose tolerance studies have been
employed in a number of situations to determine the effect and
importance of glucose in different physiological and pathological
conditions. A review of glucose tolerance in malignancy and in
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different hepatic pathologies is therefore necessary.
2.3.2 Glucose metabolism in malignancy
One of the most common situations in which glucose may be
administered, as part of nutritional management program, is in the
patient with cancer cachexia. Abnormalities of glucose metabolism in
this situation may not only indicate what precautions are necessary in
administering glucose to such patients, but may also offer some
insight into the metabolic abnormalities found in the cachectic
patient.
It has been recognised for almost 100 years that malignancy may
be associated with impaired glucose tolerance (Freund 1885). In the
early part of this century a number of studies focussed on this
phenomenon (Friedenwald and Grove 1920) principally as a means to
early detection of malignancy. Edwards (1919) accepted a normal
glucose tolerance test as strong evidence for the exclusion of a
diagnosis of cancer.
However, few held this belief, and in recent years some
extra-pancreatic malignancies have been associated with hypoglycaemia
(Chandalia and Boshell 1972, Kreisberg and Pennington 1970). A
multifactorial aetiology has been thought responsible for this, and
although the secretion of insulin-like substances by the tumours has
been suggested, (August and Hiatt 1958, Friesen and Miller 1960,
Whitney and Heller 1961, Oleesky et al 1962, Steinke et al 1962, Field
et al 1963, Floyd et al 1963, Boshell et al 1964, Volpe et al 1965),
this has been hotly disputed (Unger 1966, Bower et al 1965).
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Hypoglycaemia may also result from decreased lipolysis, decreased
gluconeogenesis or massive glucose consumption by the tumour
(Butterfield et al 1960, Landau et al 1962).
Such accounts of hypoglycaemia associated with extra-pancreatic
malignancy are rare. Much more common are accounts of impaired
glucose metabolism in malignancy (Glickman and Rawson 1956, Marks and
Bishop 1957, Jasani et al 1978 and Schein et al 1979). Glickman and
Rawson (1956) recorded intolerance to orally administered glucose in
36.7% of patients with malignancy as opposed to a 9.3% incidence in
those without cancer. This study was carried out on almost 1000
consecutive admissions to the Sloan Kettering Institute.
Schein et al 1979 regularly noted insulin resistance in the
patients they studied with malignant disease. Although they could
find no abnormality in insulin receptors they noted an increased rate
of fatty acid oxidation and gluconeogenesis associated with increased
Cori cycle activity. The Cori cycle describes the cyclic metabolic
pathway whereby glucose is converted to lactic acid and reconverted to
glucose in the liver. The only treatment which seemed capable of
correcting these abnormalities involved removal of the tumour.
This insensitivity to insulin was earlier noted by Marks and
Bishop (1957). As has already been mentioned, however, many other
factors can influence glucose tolerance and it is rare to find a
patient with cancer and no history of recumbency or sepsis, starvation
or anorexia.
Holroyde et al (1975) examined the rate of glucose production via
Cori cycle activity in patients with malignant disease. Patients with
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marked malignant cachexia had a rapid glucose turnover and high Cori
cycle activity as opposed to patients with malignancy and minimal
wasting when Cori cycle activity appeared to approach normal.
It therefore becomes apparent that altered glucose metabolism in
association with malignancy is principally found in those patients
also displaying marked cachexia.
2.3.3 Glucose metabolism in liver disease
Glucose intolerance has been documented in a number of different
liver pathologies since the early part of the century (Coller and
Troost 1929, and Althansen et al 1930). In addition to numerous
reports of glucose intolerance in hepatic cirrhosis (Kato et al 1973,
Samaan et al 1969, Riggio et al 1982, Shankar et al 1983 and Johnston
et al 1982b) it has also been found in other hepatic pathologies
including chronic active hepatitis (Alberti et al 1972), acute viral
hepatitis (Record et al 1973 and Felig et al 1970a), alcohol induced
fatty liver (Rehfeld et al 1973), paracetamol induced liver damage
(Record et al 1975a) and fulminent hepatic failure (Record et al
1975b). Reports of glucose tolerance in biliary obstruction are less
common (Solar et al 1974 and Ozawa et al 1975).
In 22 patients with hepatic cirrhosis Samaan (1969) showed a 50%
incidence of intolerance to 50 grams of glucose given orally. He
suggested this was due to a higher output of human growth hormone
(HOI) than in the patients with normal glucose tolerance. He also
noted lower circulating insulin levels in the diabetic as opposed to
non-diabetic cirrhotic patients. HGH levels in all cirrhotic patients
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were higher than in the normal controls. Riggio et al (1982) recorded
impaired glucose tolerance in 13 of 18 patients with cirrhosis of whom
5 displayed frankly diabetic clearance curves. By assessing not only
insulin levels but also c-peptide levels, an indirect method for
estimating portal insulin concentration (Bonser and Garcia-Webb 1981),
it was noted that despite glucose intolerance in cirrhotic patients
there was both an increased production of insulin, in response to
hyperglycaemia, and a reduced rate of insulin degradation (Johnston et
al 1978). Again, high HGH levels were noted in the cirrhotic patients
and also high basal free fatty acid levels were found in this group.
It was suggested by the authors that high circulating free fatty acid
(FFA) levels may be involved in producing the glucose intolerance that
was found, although a mechanism was not postulated. In 21 cirrhotic
patients studied by Shankar et al (1983) 12 had a normal response to
oral glucose, 3 had impaired glucose clearance and 6 had frank
diabetes. Again impaired insulin degradation was found in patients
with cirrhosis.
In a comparison of patients with cirrhosis and acute viral
hepatitis Hernandez et al (1969) recorded a high incidence of glucose
intolerance in patients with cirrhosis, 7 out of 9 studied, but a low
incidence in acute liver disease, 1 out 5. In a study on 25 patients,
by Megyesi et al (1967), it was suggested that insulin resistance and
hyperinsulinaemia develop early in liver disease and that this
situation may progress to diabetes. However, Hernandez et al (1969)
recorded normal IRI levels in all patients with acute liver disease
thus, in part, throwing doubt on this hypothesis.
In any study of glucose metabolism in patients with liver
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disease, a test of glucose tolerance is necessary to provide important
background information for interpretation of further results.
Abnormal glucose tolerance can be found in many varieties of liver
disease, including biliary obstruction, although it may be more likely
if the pathology is chronic in nature.
2.4.1 Nutritional assessment
Nutritional assessment is an essential first step in the
management of malnutrition (Blackburn and Bistrian 1976). Controversy
surrounds the indications for using any of the available plethora of
mechanical, biochemical and clinical investigative techniques
available. An appraisal of these techniques and of their indications
and value is therefore necessary.
The important early studies of Cuthbertson(1929, 1930, 1931,
1932, 1936) described in detail the alterations of body composition in
the injured or stressed patient. His studies noted that the increased
losses in nitrogen, sulphur and phosphorous, recordable within the
first 48 hours of injury, reached a maximum on the tenth day after
injury and thereafter decreased to basal levels. Parallel increases
in oxygen consumption, temperature and pulse rate accompanied these
metabolic changes. The immobilisation associated with injury was not
found to be sufficient cause for these losses and there was continued
nitrogen loss in ambulant injured patients, despite muscle atrophy
being reduced with movement and massage.
He further demonstrated that pyrexia alone was insufficient
stimulus to account for these metabolic losses and concluded that such
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changes were part of the body's normal response to trauma forming an
appropriate metabolic environment for tissue repair. In later studies
he noted the provision of liberal enteral nourishment, with a high
content of first class protein, significantly improved nitrogen
balance in such patients. In the intervening 50 years between these
studies and the present, changes in medical technology and awareness
have brought about increasing enthusiasm for nutritional support in
the management of the hospitalised patient. The patients studied by
Cuthbertson were trauma victims whose gastrointestinal tract was
undamaged and functional. A great need existed, however, for
intravenous solutions with sufficient nutritional value to sustain
life when gastrointestinal function was impaired through trauma or
disease. This was apparent in 1936 when Studley recorded a 33.3%
mortality, in patients with a greater than 20% weight loss, undergoing
surgery for chronic peptic ulcer disease. At that time, there was no
means available for adequate postoperative, intravenous nutritional
support. Indeed, he concluded that preoperative preparation was of
paramount importance in this situation.
Over the last decade there have been many reports of the need for
awareness of malnutrition in individuals stressed with illness and
surgery. On populations of hospitalized medical (Bistrian et al 1976)
and surgical patients (Lee 1980) up to 50% were diagnosed as having
protein-calorie malnutrition. Hill et al (1977) noted that a further
deterioration in nutritional status can be expected during hospital
treatment in those patients already malnourished on admission.
Most studies to determine morbidity and mortality rates in
relation to nutritional status employ several methods of assessment.
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There are many reasons for this practice. Some patients may be
cachectic and display severe muscle wasting, yet owing to accumulating
ascites demonstrate weight gain. Therefore the very simple, and
usually effective practice, of recording body weight in hospital, as a
function of body weight in health, is liable to misinterpretation.
Indeed the comparison of present body weight with ideal body weight
derived from actuary tables (Metropolitan Life Assurance Tables 1959)
which base calculations on a determination of patients height can also
be misinterpreted. The situation in which such comparisons are of
great value is in an examination for nutritional deficiency in
children under the age of 10 years as reported by Waterlow et al
(1977). In order to avoid the misinterpretation of such tests a
number of other methods for estimating total body protein and fat have
been devised. One of the common pitfalls of nutritional assessment,
in Western society, is that the majority of patients seen are
initially overweight. Excess adipose tissue can give the appearance
of a normally nourished state in the presence of significant muscle
wasting.
The majority of anthropometric measurements try to circumvent
this problem by assessing either the fat content or protein content of
the individual. A relatively accurate way to determine the fat
content is to measure the skinfold thickness in a number of sites
using specially designed skinfold calipers. The technique has been
described by Jelliffe (1966). Tables of standard skinfold thickness
in a number of sites have been compiled by a number of workers
(Seltzer and Mayer 1965, Frisancho 1974, Durnin and Womersley 1974 and
Burgert and Anderson 1979). Not only can such measurements on
individuals be compared with standard tables but indeed Durnin and
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Womersley (1974) related such measurements to an estimate of total
body fat content. The estimate of total body fat content was arrived
at after weighing a number of volunteers, and estimating total body
volume by displacement in water. This allowed a calculation of total
body density. From this and a knowledge of the density of adipose
tissue an estimate of fat free body mass could be computed.
The limitations in the use of skinfold thickness measurements
relate to alterations in body composition with age and sex. As
individuals become older there is usually an increase in the ratio of
adipose tissue to lean body mass, and women have a higher ratio of fat
to muscle. There have also been reports of differences between races
(Newman 1956). In addition, unless a rigorous technique is used wide
variations in results can occur (Ruiz et al 1971).
MAMC = MAC - TT X TSF
MAMC = Mid arm muscle circumference
MAC = Mid arm circumference
TSF = Triceps skinfold thickness
Fig. 2 Calculation for mid-arm muscle circumference
Not only can a record of skinfold thicknesses give an estimate of
total body fat content, but they can also give indirect evidence of
muscle content. Such evidence is based on the assumption that the
triceps skinfold thickness is approximately twice the average
thickness of the skin around the middle of the upper arm, including
subcutaneous tissue. By using the calculation in Fig. 2 the "Mid-arm
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muscle circumference" can be calculated. The term mid-arm muscle
circumference is slightly misleading, and requires careful
interpretation, as the measurement also includes the humerus.
A number of workers have prepared tables of norms, for such
measurements after studying large numbers of healthy volunteers.
(Gui^iey and Jelliffe 1977, Frisancho 1974 and 1981). The comparison
of such figures with those derived from malnourished patients gives an
estimate of the degree of muscle loss or wasting in terms of a
reduction in arm muscle circumference or cross-sectional arm muscle
area. A novel way to estimate arm muscle mass has recently been
described (Frank et al 1981) in a very visual manner, by the simple
manoeuvre of taking an xray of the upper arm and measuring directly
muscle thickness.
In an effort to devise a simpler and more rapid clinical measure
of muscle wasting in hospitalized patients or out-patients, Klidjian
et al (1980) made extensive use of hand grip dynamometry to estimate
not only forearm muscle bulk but also forearm muscle function. It was
found that this was very sensitive preoperative test for predicting
complications from surgery.
The use of biochemical tests has also been explored as a means to
determine nutritional status. The most common test used is
measurement of serum albumin. Such a test is of limited usefullness.
Albumin has a very large body pool and a relatively long biological
half life, approximately 3 weeks. This means that not only does it
respond to changes in nutritional status slowly it also responds to
nutritional repletion equally slowly. Serum transferrin has also been
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studied as its half life of 8 days is slightly shorter. However other
factors, including iron deficiency, can affect transferrin levels.
The plasma proteins that may have most value are those with the
shortest half lives and smallest body pools including
thyroxine-binding prealbumin and retinol-binding protein (Ingenbleek
et al 1975 and Shetty 1979).
Another measure which incorporates both anthropometric and
biochemical data was first described by Viteri in 1970 and that is the
creatinine height index. This estimate of nutritional status assumes
a uniform and reproducible creatinine excretion per unit of muscle.
By referring to tables of creatinine excretion recorded on normal
individuals of known height, a reduced creatinine excretion compared
with the anticipated figure for normal individuals of the same height
wouldt imply that the individual in question had a reduced muscle
bulk. Indirect evidence of muscle wasting can therefore be produced.
This measurement was used extensively by Bistrian et al (1975) and
Blackburn et al (1977).
The problem with all these tests is that they either make such
general measurements, as in the case of weight or ideal weight, that
they can be seriously misinterpreted, or, they are so specific, as in
the case of arm muscle circumference or grip strength, that they
cannot to take into account total body protein content.
Commonly the basic intention of nutritional status measurements
is to indicate those patients at risk of serious complications from
surgery. Impaired nutritional status has been recognised as the
commonest cause of secondary immunodeficiency (Chandra et al 1968)
which has been shown to lead to increased susceptibility to infection
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(Scrimshaw et al 1968, Carney et al 1980, Chandra and Newberne 1977).
It must be stressed, however, that these studies reflect the findings
in developing countries and relate to paediatric protein calorie
malnutrition. The relationship between nutritional status and
immunological competence has been investigated by a number of methods
(Chandra and Scrimshaw 1980). The value of a variety of delayed
hypersensitivity skin test measurements, total blood lymphocyte
concentration and the concentration of circulating T-cells have all
been used to assess immune responsiveness (Chandra and Schrimshaw
1980, Christou 1979a, 1979b).
In a recent review of the current literature on this subject Dowd
and Heat ley (1984) conclude that there is only a limited understanding
of the effect of nutritional repletion on the avoidance of
complications associated with secondary immunodeficiency. Much work
is still required in this field.
Two further tests are available which estimate the total body
content of a number of different elements. There are considerable
data in the literature supporting the relationship between total body
potassium and total body nitrogen (Harvey et al 1973). It has long
been known that the ratio of potassium to nitrogen content in all soft
tissues in both normal and pathological states is constant (Talso et
al 1953a, 1953b, 1960). The measurement of total body potassium
40
relies on the occurrence of the very stable radio isotope K as
approximately one atom in every ten thousand of naturally occurring
40
potassium atoms. The amount of K in any individual can be
recorded by means of a total body counting chamber (FIG. 3). From the
result an extrapolated figure for total body potassium can be produced
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Fig. 3. Total body counting chamber
which takes into account variations in height, weight and age of the
individual (Goode and Hawkins 1978).
The use of in vivo neutron activation analysis has gained
popularity, in recent years, as a means of assessing body composition
(Anderson et al 1964, Hill et al 1978, 1979, Oxby et al 1978, Macfie
et al 1981). This technique can produce very convincing evidence to
identify the appropriate combination of intravenous solutions for
maximal anabolism (Macfie et al 1981).
No matter how attractive such techniques are their routine
application to the average clinical situation is uncommon, the main
reason being the prohibitive cost of the basic equipment. Many
clinical studies which include nutritional status measurements, as
part of their protocol, record a large number of anthropometric and
biochemical parameters. This is done in an effort to present a
comprehensive and balanced account of nutritional status measurements
in the individuals being studied, in order to avoid the pitfalls of
individual tests (Mullen et al 1979, Maclean 1975, Meakins et al 1977,
Kaminski et al 1977, Buzby et al 1980). Baker et al (1982) recently
presented data which suggested the assessment of nutritional status
based on routine clinical history and examination was as valuable as
objective anthropometric and nutrition-related biochemical
measurements in the prediction of postoperative morbidity.
Controversy therefore exists between the use of complex
anthropometric measurements and clinical observation in determining
nutritional status. That they may be equally useful confirms their
mutual value as a means of standardising estimates of nutritional
status (Baker et al 1982, Russell and Jeejeebhoy 1983).
PATIENTS
"So many gods, so many creeds
So many paths that wind and wind,
While just the art of being kind
Is all the sad world needs."
Ella Wheeler Wilcox (1855-1919).
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3.1.1 PATIENTS
This study was approved by the Royal Postgraduate Medical School
Ethics Committee in the Hammersmith Hospital. All patients gave fully
informed consent to each part of the study.
The 23 patients participating in this study had been admitted to
hospital for management of a gastrointestinal or intra-abdominal
malignancy (TABLE 1). In 13 the malignant process had caused
obstructive jaundice to develop, the remaining 10 having normal
bilirubin levels. Obstructive jaundice, in this instance, was
diagnosed with a history of dark urine and pale stool, a serum
bilirubin level above 100umol/l, an elevated serum alkaline
phosphatase level and an abdominal ultrasound examination
demonstrating dilated intra-hepatic ducts. ,
In the jaundiced group there were 7 males and 6 females with ages
ranging from 41 to 74 years, while the non-jaundiced, control group of
patients comprised 8 males and 2 females whose ages ranged from 22 to
80 years (TABLE 2).
It was planned to study each patient on 2 separate occasions:
firstly, on admission to hospital, before any treatment had been
offered; and, secondly, on resumption of an enteral diet
postoperatively. In addition, in the case of the jaundiced patients,
the bilirubin level was required to drop below 100umol/l, or to at
least half the preoperative level before the postoperative tests were
carried out. In this way it was hoped each patient could act as his
own control. For several reasons, discussed later, postoperative
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TABLE 1. Sex, age and relevant pathology of patients in study
Jaundiced Non-jaundiced
13 (M=7, F-6) 10 (M-8, F-2)
Age range 41-74 22-80
Mean age 60 61
TABLE 2. Summary of patients ages and sexes.
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3.2.1 Methods - Introduction
On admission, after the diagnosis had been made, each patient was
examined for evidence of nutritional deficit. A number of tests were
employed, both anthropometric and serological, to help determine
nutritional status.
Included in these measurements were an assessment of weight loss,
deviation from ideal weight, skinfold thickness over the triceps,
biceps, suprailiac and subscapular areas. This allowed an estimation
of fat free mass (Durnin and Womersely 1974) as well as mid arm muscle
circumference (Frianscho 1974). Additional measurements of mid
forearm muscle circumference and grip strength were carried out as
part of a multi-centre study as described by Klidjian et al (1980).
In order to provide a broader nutritional assessment, serum albumin,
thyroxine binding prealbumin and transferrin were measured and total
body potassium estimated.
Creatinine clearance, twenty-four hour urine volume, urinary urea
and electrolyte excretion were measured to determine renal function on
the day of study. Hepatic function was recorded with routine
laboratory estimates of bilirubin, aspartate transaminase and alkaline
phosphatase. In no patient was there any evidence of sepsis at the
time of study. Additional data collected included the duration of
illness and length of post-operative stay.
Glucose and alanine clearance levels were carried out on
consecutive days. Patients were randomly offered either a glucose
tolerance test or an alanine tolerance test on the first day and the
second test on the following day.
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3.2.2. Intravenous Glucose Tolerance Test.
After an overnight fast of eight to ten hours, an intravenous
cannula was inserted into a large ante-cubital vein and 10ml of blood
taken for glucose and free fatty acid (FFA) estimation with part of
the sample being stored to allow hormone estimation at a later date.
The samples were anticoagulated in lithium heparin tubes
containing lOOul of apoprotenin. lOOul was immediately deproteinised
in 1ml of uranyl acetate solution, the remainder being centifuged at
8000 r.p.m. for 15 minutes. The plasma was then divided into
approximately 2ml and 6ml portions, the former for FFA estimation and
the latter stored at -15°C for later hormone assay.
A rapid infusion of 25g of aqueous dextrose solution was then
given Winto the opposite arm over a period of 2-3 minutes. The timing
of further samples was made from the end of injection. Further blood
samples were taken from the indwelling intravenous cannula and
following each sample the cannula was flushed with 10ml of normal
saline. Prior to each sample being collected 10ml of blood mixed with
the residual intra-cannular saline was withdrawn to ensure an
undiluted sample was collected. The mixed blood was rapidly returned
to the patient before thrombus formed in order to limit blood loss
over the test period (Fig. 4).
Following the glucose injection six further 10ml samples were
collected in this fashion at ten minute intervals. At the end of the
test the intravenous cannula was removed and the wound dressed.
Fig.4.
INTRAVENOUSGLUCOSETOLERANCEST






Glucose was assayed enzymatically (Werner et al 1970) and FFA
assayed colorimetrically (Duncombe 1964) . All analyses were carried
out twice and the average value recorded. The problems encountered in
this procedure were related to the FFA assay. It was already known
that haemolysis interfered with the analysis, however, once sufficient
patients had been studied it became evident that significantly higher
readings for FFA levels were being obtained in the jaundiced
patients.
Subsequent analysis of FFA levels in normal plasma with varying
amounts of bilirubin added, revealed a similar alteration to those
found in the plasma of jaundiced patients. Since this problem was
discovered toward the end of the study appropriate action to abolish
the effect of the bilirubin contamination was not introduced as it
could only be applied prospectively to a small number of results. A
significant difference between FFA levels in jaundiced and control
patients cannot therefore be considered to be real, but the rate of
change of FFA levels can still be studied.
3.2.3 Intravenous Alanine Tolerance Test
This test was carried out in a similar fashion to the glucose
tolerance already described. After an overnight fast of 8-10 hours an
indwelling cannula was inserted into a large forearm or antecubital
vein. A 17ml venous blood sample was collected, 8ml being immediately
deproteinized in ice cold perchloric acid and 10ml placed in a lithium
heparin tube containing lOOul of aprotinin. lOOul was immediately
deproteinized in uranyl acetate for glucose estimation.
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An aqueous solution containing 12g of L-alanine was then injected
intravenously in the opposite arm over 3-5 minutes. Every 10 minutes
over the next hour, one further 17ml sample was collected and stored
as detailed above. Between each sampling time the intravenous cannula
was flushed with 10ml of normal saline. To ensure the collected sample
was undiluted, prior to each sample being drawn, 10ml of blood mixed
with saline was drawn off and quickly replaced after sampling, before
thrombus formed (Fig. 5).
All blood samples were centrifuged immediately at 8000 r.p.m. for
15 minutes and the supernatant underwent enzymatic analysis for
glucose (Werner et al 1970), pyruvate (Czok and Lamprecht 1974),
D-(-)-3-hydroxybutyrate (Williamson and Mellanby 1974), alanine
(Williamson 1974), lactate (Hohorst 1965), and colorimetric analysis
for free fatty acids (FFA) (Duncombe 1964).
As with the glucose tolerance test it was discovered at a late
stage in the study that the high bilirubin level in the serum of the
jaundiced patients interfered with the colorimetric assay for FFA. No
correction could be made for this so only a comparison of clearance
rate of FFA can be considered significant. Comparison of individual
levels is not possible.
In this test, as in the glucose tolerance test, plasma samples
treated with apoprotenin were stored at -15°C for later hormone
analysis. At the end of the sampling period the intravenous cannula
was removed and the wound dressed.
During administration of the alanine solution some patients
























alanine infusion abolished the symptoms, none of which persisted for
more than 1 or 2 minutes.
A 12g intravenous dose of alanine was chosen as this is the
amount used by other workers (Elia et al 1980, Royle & Kettlewell
1981) thus allowing a direct comparison of this work with theirs.
Initially it was considered that this would produce unphysiological
levels of alanine in the circulation therefore the first patient
studied was offered only 5g of alanine. However, as can be seen in
TABLE 3 and Fig. 6, there is little evidence of a change in blood
alanine level between the peak level and 1 hour level. Unfortunately
the fasting level is missing as it was not suitable for assay.
The remaining 22 patients studied had a mean fasting level of
0.145mmol/l with a range from 0.071-0.291mmol/l. Therefore, although
it is likely that this patient's blood alanine level rose in response
to the 5g alanine infusion, the rise was minimal and the clearance
rate negligible. This patient was not involved in further studies.
For these reasons the apparent convention for administering 12g to
each patient was adopted. Since this was not offered as a weight
related dose, some variation in the peak level was anticipated as
result of differing body bulk among the patients studied. It was also
found that peak levels were 3 times lower than would be expected after
a 12g injection, and did not match those found in previous work (Elia
et al 1980, Royle & Kettlewell 1981).
It appears there is a multi-exponential clearance of alanine from
the circulation, but 10 minutes after injection of alanine the
clearance curve becomes effectively linear. To clarify this point a
number of early samples, from 1 minute to 10 minutes, were collected








Table 3. The clearance of 5g of L-alanine

















and the results, TABLE 4 and Fig. 7, demonstrate rapid clearance of
alanine and a peak level in keeping with the expected level.
In the earlier studies of Elia et al (1980) and Royle and
Kettlewell (1981) the timing of samples started at the beginning of
the alanine infusion. For this reason their recorded peak level was
higher than is found in this study where timing began at the end of
the infusion. Quality testing of random samples of the alanine
solution confirmed its concentration at the time of injection to be
that calculated by the pharmacy department where the solutions were
prepared.
Of the initial 22 patients studied 14 did not undergo
postoperative study. Four patients refused consent for further
investigation. Six patients did not undergo surgery. One patient
died preoperatively and in 3 others bilirubin levels were not
sufficiently improved postoperatively, by the time of discharge in 2,
and eventual death in the third, to act as reasonable controls. There
were only 8 patients in whom any postoperative studies could be
carried out.
3.2.4 Anthropometry and nutritional assessment
The nutritional status of each patient admitted to this study was
recorded in a variety of ways at the time of both the preoperative and
postoperative studies. Measurements of percentage weight loss were
made in two ways: firstly, by comparing the patient's measured weight
with their reported weight in health; and secondly, by comparing their
measured weight with the anticipated weight relative to their height






































Fig. 7. The early clearance of 12g of L-alanine
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(Metropolitan Life Assurance tables 1959). Other physical
measurements included grip strength (Klidjian et al 1980) and skinfold
thickness (Jelliffe 1966). Using these results an estimate of
nutritional status can be made by comparison with tables of normal
values (Frisancho 1974). In addition, an estimate of fat free mass
(or lean body mass) was made by reference to tables produced by Durnin
and Womersley (1974). A blood sample was taken for estimates of
plasma albumin, transferrin and thyroxine binding pre-albumin, and




Owing to the small number of samples in each group under study it
was assumed that no population of data formed either a normal
distribution or a "t" distribution. For this reason data populations
are summarised by using the median as the midpoint of the values and
the range to illustrate the spread of data. The Mann Whitney U test
was considered the most suitable analytical test for comparing ranges
(Siegel 1959).
The clearance curves for alanine and glucose are assessed in a
number of ways in order to summarise the data accurately as well as
present them in a manner which allows easy comparison with previous
studies. Linear regression analysis, using the method of "least
squares" (Armitage 1977), was employed to test each substrate curve
for 'linearity and deviation from the X-axis. The "F" distribution
(Armitage 1977) was employed to examine the significance of such
linearity or deviation. The Chi squared test with Yate's correction
for small numbers and Fisher's exact test (Seigel 1959) were used to
compare proportional differences.
The clearance rates for both alanine and glucose were expressed
in 2 further ways. The substrate half-life was calculated in the
standard fashion and its reciprocal (k) the rate constant recorded.
Finally, a clearance rate, taking into account the patients weight and
substrate distribution volume was calculated (Elia et al 1980).
Graphic representation of data has been introduced to help in its
description in certain parts of the text. In order to simplify the
drawing of the graphs, while still offering some information as to the
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range of values, mean values and standard errors on the mean are
represented.
Many calculations, including regression analysis, was carried out
with the help of standard spread sheet software running on an Apple II
*
plus 64K micro-computer.
Accuracy of analytical methods
The percentage substrate recovery was as follows:
alanine 98.5 ±3.2 S.D.
glucose 99 ±4.25 S.D.
lactate 103.5 ±6.3 S.D.
pyruvate 98.7 ±3.75 S.D.
acetoacetate 104 ±5.4 S.D.
FFA 97 ±4.3 S.D.




Substrate levels in the preoperative studies are recorded in
TABLES 6 to 29 all of which can be found in Appendix I. The results
for patients with biliary obstruction and non-jaundiced controls are
in separate tables. For each set of results a separate summary of
regression analysis indicates whether a linear correlation exists
between values and if a slope is present. A separate table, following
each set of results records comparisons between groups of fasting
levels and peak levels or clearance rates for each substrate.
The labelling of each column of results, 1-12 in the jaundiced
group and 1-10 in the non-jaundiced group, is specific for a single
patient. Not all patients underwent all tests. The tables of results
indicate by number which were involved at each stage.
4.2.1 Preoperative alanine tolerance test - Alanine Levels.
The methods used for analysing the clearance of alanine from the
circulation have been adapted from those developed for analysis of
glucose clearance curves. A full description of the required
mathematical transformations appears in section 4.3.1.
In patients with biliary obstruction, fasting levels of alanine
ranged from 0.07-0.22mmol/l (Table 6a) with a median of 0.135mmol/l
(Table 8), while in the control patients, fasting levels ranged from
0.11-0.29mmol/l (Table 7a) with a median of 0.168mmol (Table 8).
There is no significant difference between these ranges of values.
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Alanine clearance was calculated in 4 different ways. In all
calculations the slope of the curves between the 20 and 60 minute
samples was measured to determine clearance rates. Linear regression
analysis, of the collected values at each time point, demonstrates a
linear relationship between these values (Tables 6b, 7b). However,
some workers (Elia et al 1980, Royle and Kettlewell 1981), concerned
with exponential nature of the clearance slope, consider a logarithmic
transformation of these data allows a more accurate estimate of the
clearance rate. Such transformations have been used here and will
allow comparisons to be made with the work of others.
With the data represented on semi-logarithmic graph paper the
alanine half life can be measured and a rate constant (k) calculated.
In addition, a clearance rate which takes into account the alanine
distribution volume and individual body weights was calculated (Newton
et al 1978). The results of these analyses are summarised in TABLE
8. No differences were found between the clearance rates in the
jaundiced and non-jaundiced groups by any method.
A graphic representation of these data can be seen in Fig. 8.
Fasting levels, peak levels and slopes appear remarkably similar. The
range of values at each time point is represented by the standard
error on the mean.
4.2.2 Preoperative Alanine Tolerance Test - Glucose Levels.
Fasting levels of glucose in jaundiced patients and non-jaundiced
patients ranged from 2.97-5.44mmol/l (Table 9a) and 3.01-5.50mmol/l
(Table 10a), respectively. Median values were 3.635 and 3.71,
I2gL-AlanineT ME(m ns) infusion Fig.8.Preoperativealan neclearancecurves{
I
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respectively, (Table 11a), there being no significant difference
between the groups. Regression analysis revealed that all points
conformed to linearity and there was no significant deviation from
horizontal, (Tables 9b and 10b), although there appeared to be a
slight rise in glucose levels throughout the study with median peak
levels being 4.71 and 4.265mmol/l in the jaundiced and non-jaundiced
group respectively (Table lib).
In addition to rise in blood glucose being insignificant, it is
noteworthy that the peak levels occurred at different times in each
curve. In some, the fasting level was equal to the peak level.
4.2.3 Preoperative Alanine Tolerance Test - Free Fatty Acid (FFA)
Levels.
Fasting FFA levels ranged from 0.46-1.32mmol/l (Table 12a) and
O.41-O.97mmol/1 (Table 13a) in the group with biliary obstruction and
the non-jaundiced group respectively. The median levels in each group
were 0.8 and 0.595mmol/l respectively, representing a significant
difference between the groups. However, the FFA clearance rate in
response to the alanine load ranged from -0.006 to -0.Ollmmol/min
(Table 12a) in the jaundiced group and from 0 to -0.009 in the control
group, (Table 13a). Median clearance rates are identical at
-0.007mmol/min. This is demonstrated well on the graphic
representation of the mean slopes for each group in Fig. 9.
Regression analysis, Tables 12b and 13b, confirms the linearity of the
values represented and the deviation from horizontal.
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Fasting levels, however, are significantly different with the
median value for patients with biliary obstruction being 0.8mmol/l and
that for the control patients being 0.595mmol/l. The reason for this
difference has been discussed in section 3.2.3.
4.2.4 Preoperative Alanine Tolerance Test - Lactate Levels
Fasting lactate levels are similar in both groups ranging from
0.27 to 2.31mmol/l in the groups with biliary obstruction (Table 15a),
and from 0.35 to 1.38mmol/l in the control group (Table 16a). Median
fasting levels were 0.83 and 0.795mmol/l respectively (Table 17a).
There is no significant difference between these values. Median peak
levels of 1.38 and 1.185mmol/l (Table 17b) imply an increased lactate
release throughout the test period. Linear regression analysis
(Tables 15b and 16b) suggest that although both sets of data conform
to a straight line, there is no significant deviation from the
horizontal axis.
4.2.5 Preoperative Alanine Tolerance Test - Pyruvate Levels.
Fasting pyruvate levels are similar in both groups ranging from
0.03 to 0.14mmol/l (Table 18a) in the jaundiced group and 0.03 to
0.16mmol/l in the non-jaundiced group (Table 19a). Median fasting
values were 0.109 and 0.094mmol/l respectively (Table 20b). There is
no significant difference between these results. Median peak levels
of 0.159 and 0.142mmol/l (Table 20b) imply an increased pyruvate
release throughout the test. Linear regression analysis (Tables 18b
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and 19b) suggests that although both sets of data conform to a
straight line there is no significant deviation from the horizontal
axis.
4.2.6 Preoperative Alanine Tolerance Test - Acetoacetate Levels.
This assay proved particularly troublesome and many samples were
unsuitable for testing. Of the results obtained, fasting acetoacetate
levels ranged from 0.05 to 0.14mmol/l (Table 21a) in the jaundiced
group, and 0.05 to 0.11mmol/l (Table 22a) in the non-jaundiced group.
Median levels were 0.09 and 0.087mmol/l respectively (Table 23a) there
being no difference between groups. Peak acetoacetate levels were
slightly higher than fasting levels, with median levels of 0.014 and
0.101mmol/l respectively (Table 23b). Linear regression analysis
indicated no evidence of a gradient in otherwise straight lines
(Tables 21b and 22b). However, ranges of values were very large and
differences between fasting and peak levels not significant.
4.3.1 Preoperative Intravenous Glucose Tolerance Test - Glucose
Levels.
The intravenous glucose tolerance test was intensively studied as
a diagnostic tool between 1930 and 1970 (Althausen et al 1930,
Amatuzio et al 1953, Greville 1943, Hamilton and Stein 1942, Lundbaek
1962, Marks and Bishop 1957, Samols and Marks 1965). Such a test can
be analysed in a variety of ways. Several methods have been used here
to allow comparison of these data with the results of others.
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The small populations of subjects in this study, 11 with biliary
obstruction and 8 controls, provide too few data for testing with the
Student's t test. The results have therefore been expressed in terms
of medians and ranges with the Mann Whitney U test being employed to
compare ranges.
A direct comparison of the ranges of fasting glucose levels in
jaundiced and control patients showed no signficant difference between
the groups (TABLE 26). The individual values are recorded in TABLES
24a and 25a.
Analysis of the clearance of the intravenous glucose load is
expressed in a variety of ways, similar to the description of alanine
clearance, already discussed. Multiple linear regression analysis
(Armitage 1977) reveals that the collected clearance slopes between
the 20 and 60 minute sample times present a linear relationship which
deviates significantly from the horizontal (TABLES 24b and 25b)
A comparison of mean glucose clearance slopes for the jaundiced
and non-jaundiced patients reveals no significant difference (TABLE 26
and Fig. 10). However, many workers have preferred to express the
clearance rate as a function of the semi-logarithmic plot of the blood
glucose values (Hamilton and Stein 1942, Greville 1943, Amatuzio et al
1953, Hlad and Elrick 1959, Lundbaek 1962 and Samols and Marks 1965).
This method eliminates or minimises any error due to the slight
exponential nature of the curve between the 20 and 60 minute samples.
If the results are plotted on semi-logarithmic graph paper the
substrate clearance half-life can be measured directly (Fig. 11).




Fig. 11. Graphic measurement of alanine half life
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than that in the control group, 73 compared to 47.5 minutes,
respectively, there is no significant difference between ranges (TABLE
26).
Once the value for the half-life has been measured a rate
constant (k) can be calculated.
k = 0.693/t_ (units/min)
U • 3
This represents the logarithm to the base "e" of the ratio of the
blood glucose curves divided by the time between samples. Since
tg is the half life, the ratio of blood glucose levels for that
time is by definition 2:1.
loge2 = 0.693
This can be presented in a simpler form by multiplication by 100. The
units of measurement then represent the percentage decrease in blood
glucose per minute.
k = 0.693 x 100/tn (%/min)U • 3
Comparing k values for the jaundiced and non-jaundiced groups
reveals median values of 0.91 and 1.47 (%/min). There is no
significant difference between the ranges of results in the 2 groups
(TABLE 26). In addition, a clearance rate which takes into account
the glucose distribution volume and individual body weights was
devised (Newton et al 1978). The distribution volume is calculated by
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extrapolating the slope formed with the logarithmic values of the
glucose concentration to the Y axis. This value can be considered the
original glucose concentration (Gq). When the quantity of glucose
infused (G^) is divided by Gq the resulting figure represents the
distribution volume.
DISTRIBUTION VOLUME = (1)
If this is then divided by the body mass (M) a value for
distribution volume per Kg body weight is obtained.
DISTRIBUTION VOLUME per Kg BODY WEIGHT = G^/Gq x 1/M (1/Kg)
The multiplication of this figure by the rate constant "k",
expressed in units per minute, provides a value for the clearance rate
relative to the distribution volume per Kg body weight.
CLEARANCE RATE = G./G x 1/M x 0.693/tn , x 1000 (ml/min/Kg)x o u • d
The use of this figure should minimise any error brought about by
differences in body weight and distribution volume between
individuals. When applied to the 2 groups under study here median
values of 1.51 and 2.06 (ml/min/Kg) were obtained. There was no
significant difference between the ranges of these clearance values.
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4.3.2 Preoperative Intravenous Glucose Tolerance Test - FFA Levels.
Fasting FFA levels were significantly different between the
groups ranging from 0.26 to 1.52mmol/l (Table 27a) in the jaundiced
group and 0.30 to 1.00mmol/l (Table 28a) in the non-jaundiced group.
The median values were 0.61 and 0.365mmol/l respectively (Table 29a).
The slopes ranged from 0 to -0.013mmol/min (Table 27a) in the
jaundiced group and from -0.002 to -0.0l4ramol/min (Table 28a) in the
non-jaundiced group. The median slopes were -0.007 and -0.005mmol/min
respectively (Table 29b) and were not significantly different.
Graphic representation of these data is displayed in Fig. 12.
4.4.1 Postoperative Alanine Tolerance Test
For reasons already explained only 8 of the patients studied
preoperatively were suitable for study postoperatively. Although this
means the comparisons of pre and postoperative values limit
statistical evaluation, the size of the groups compare well with those
in other studies (Elia et al 1980).
As can be seen in Table 30a fasting alanine levels do appear
higher in the jaundiced group than in the non-jaundiced group with
median fasting levels at 0.19 and 0.14mmols respectively but the
differences are not great enough and numerous enough to suggest two
separate distributions of results. Median clearance rates of -0.0125
and -0.015mmol/min are statistically similar. When individual
patients are considered and the pre and postoperative values are
compared, from Tables 6a, 7a and 30a, the following results appear.







doubled in 2 of 4 patients but fell in the remaining 2. The mean
change was an increase of 0.055mmol/l. There was also a slight
increase in the average clearance rate, for these patients, by
0.004mmol/min although 2 patients showed no change in clearance. The
fasting levels in the non-jaundiced group showed a fall
postoperatively by an average of 0.06mmol/l. However, preoperative
and postoperative results are available on only 2 patients in this
group. Clearance rates showed slight increase similar to that found
in the jaundiced group with a mean increase of 0.004mmol/min. The
changes in clearance rate in both groups is minimal. However,
although only a small number of results are available, this suggests
that, in the postoperative period, muscle catabolism in the jaundiced
group increases while in the non-jaundiced group it decreases.
A comparison of pre and postoperative glucose levels can be made
by reference to Tables 9a, 10a and 31a. The mean fasting glucose
level in jaundiced patients was lower postoperatively by 0.53mmol/l
and was higher in the control group by 0.09mmol/l. Statistical
evaluation suggests that it is unlikely that these changes are caused
by anything other than chance. There was a negligible change in peak
glucose levels in both groups.
No significant changes in FFA metabolism were noted (Tables 12a,
13a, 14a and 32a). On comparing fasting and fasting and peak pyruvate
levels in Tables 18a, 19a and 34a no changes were noted between mean
pre- and postoperative levels. A comparison of acetoacetate levels
was impossible owing to the large number of missing values in Tables
21a, 22a and 35a.
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A comparison of mean and median postoperative lactate levels
(Table 5) shows that in the group with biliary obstruction there is an
increase in the fasting levels after surgery which almost reaches
significance when comparing ranges with the Mann Whitney U test.
However, in this situation the McNemar test (Seigel 1959) is more
appropriate and demonstrates it to be only a trend and not a
significant change. This trend is not seen in the control group
(Tables 15a, 16a, 33a).
4.5.1 Postoperative Intravenous Glucose Tolerance Test.
As with the postoperative alanine tolerance test the most
valuable way to assess the data relating to postoperative glucose
clearance is by comparing them with the appropriate individual
preoperative levels. For these analysis Tables 24a, 25a, 27a, 28a,
36a and 37a need to be examined.
Fasting glucose levels in the jaundice group were not markedly
different before and after surgery. The glucose clearance rates were
almost identical on both occasions. Similarly, FFA fasting levels and
clearance did not differ significantly before and after surgery.
4.6.1 Nutritional Status Measurements
Nutritional status, in terms of muscle mass, is an important
consideration when examining alanine clearance as the ability of the
individual to release alanine from muscle is likely to be related to
muscle mass. The results of a number of anthropometric and
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Table 5
The alanine clearance test
Fasting lactate levels before and after surgery (mmol/1)
Patient Preop Postop
4 1.08 0.96
Jaundiced 5 0.82 0.64
8 0.72 1.64
9 0.27 1.02
Mean (SD) 0.72 (0.34) 1.07 (0.42)
Median 0.77 0.99
6 0.56 0.37
Non-jaundiced 9 0.54 0.96
10 0.99 0.88
Mean (SD) 0.70 (0.25) 0.74 (0.32)
Median 0.56 0.88
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biochemical measurements are recorded in Tables 38 and 39. As can be
seen from the comparison of individual ranges no difference in the
percentage of weight loss, arm muscle circumference, grip strength or
lean body mass for the jaundiced and non-jaundiced patients could be
found (Fig. 13). Serum albumin, transferrin and thyroxine binding
prealbumin were also similar. Total body potassium values were only
available on jaundiced patients.
Although there were no significant differences between the groups
of patients with regard to anthropometric assessment this did not
necessarily imply that an abnormality in one method of assessment
could predict the trend in another measure. By comparing normal and
abnormal values of each method of assessment with all other methods,
very little correlation could be found.
Despite the low numbers having total body potassium estimations a
significant correlation, p = .01, was found between these values and
prealbumin levels. In addition, prealbumin levels correlated well
with serum albumin levels (p < .05) and arm muscle circumference with
estimates of deviation from ideal body weight. However, no other
relationships were found.
Renal function, (Table 40), recorded in blood urea and creatinine
levels, urinary urea output and creatinine clearance was also similar
between study and control groups. Difficulty was encountered in
collecting 24 hour urine specimens on some of the control patients.
An examination of serum albumin, alkaline phosphatase and
aspartate transaminase in Table 41 revealed significant differences
between the jaundiced and non-jaundiced groups in all parameters.
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Alanine plays a central role in protein and amino acid metabolism
in peripheral muscle, and in hepatic gluconeogenesis. It is
quantitatively the major gluconeogenic amino acid (Felig 1973).
Following protein degradation in the peripheral muscle, during a
period of fasting or stress, it acts as a transport molecule between
the periphery and the liver where it is converted to urea and the
carbon skeleton necessary for gluconeogenesis. In the fed individual
excess circulating amino acids are converted to alanine thus also
contributing to this metabolic cycle.
5.2.1 Preoperative alanine clearance study
Since 1973 when Felig first reviewed the importance of alanine in
muscle metabolism the alanine clearance study has been employed by
several workers in an attempt to assess the rate of muscle catabolism,
and its controlling factors, in starved or stressed individuals. In
most studies patients received a bolus of L-Alanine following an 8-12
hour fast, and the substrate, metabolite and hormonal concentrations
were recorded for 60 minutes following infusion (Royle et al 1977,
Elia et al 1980, Royle and Kettlewell 1981, Fernandes and Blom 1974,
Genuth and Castro 1974, Nosandini et al 1981, Felig et al 1969b,
Swaminathan et al 1981 and Muller et al 1971).
The dose of alanine being offered varied between centres. Some
workers used a standard dose of 10 or 12g L-alanine infused over 3-4
minutes (Royle et al 1977, Elia et al 1980, Royle and Kettlewell 1981,
Felig et al 1969b, Swaminathan et al 1981) while others offered a
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weight related dose (Muller et al 1971, Genuth and Castro 1974,
Fernandes and Blom 1974, Nosandini et al 1981). In only one study
(Muller et al 1971) dogs were the subject under study, and in another
(Genuth and Castro 1974) the alanine was offered orally instead of
parenterally. The present study was conducted in a similar manner to
that used by Royle et al (1977), Elia et al (1980) and Royle and
Kettlewell (1981).
In an alanine clearance study an examination of fasting alanine
levels and alanine clearance rates provides information about its
production from muscle and its hepatic clearance. In the present
study preoperative fasting alanine levels were similar in both
jaundiced and non-jaundiced groups. This would imply that either the
rates of muscle alanine release and hepatic clearance are similar in
both groups or any variations in one of these mechanisms is
compensated for by an appropriate change in the complementary
process.
When fasting levels in this study are compared to those in other
studies it can be seen that they are significantly lower than those
found by most other workers. Felig (1969b) recorded fasting alanine
levels of 0.25mmol/l, almost twice the median levels found here.
Similarly, Royle et al (1977), Elia et al (1980) and Royle and
Kettlewell (1981) noted mean fasting levels in excess of 0.22mmol/l, a
level exceeded in only 2 non-jaundiced subjects and no subjects with
biliary obstruction in the present study. Indeed even in the group of
patients with muscle dystrophy, studied by Elia, the mean level was
0.224mmol/l. Swaminathan (1981) recorded fasting alanine levels above
0.5mmol/l in healthy subjects, his lowest mean value, of 0.297mmol/l,
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being found in a postoperative group without sepsis.
Since no "normal" controls were included in this study absolute
comparisons with other work cannot be made. Nevertheless, the
homogeneity of values in the present work and the use of standard
solutions to test the analytical methods confirms the validity of the
values recorded here.
The implication is, therefore, that in malignant disease, a
situation not previously studied with the alanine clearance test, a
mechanism seems to prevail which maintains unusually low fasting
alanine levels.
Royle and Kettlewell (1981) noted that ketone bodies,
acetoacetate and beta-OH-butyrate, exert a controlling influence on
alanine released from muscle. Beta-OH-butyrate levels were not
recorded in this study but the normal fasting ratio of acetoacetate to
beta-OH-butyrate is 1:1 (Swaminathan 1981, Royle and Kettlewell 1981,
Elia et al 1980, Nosandini 1981). Comparisons with the results of
others reveals that the acetoacetate levels in this study are higher.
If, as reported by Royle and Kettlewell (1981), ketone bodies exert a
controlling influence on the release of alanine from muscle this may
account for the lower fasting alanine levels seen here. Although
fasting levels of pyruvate and lactate are similar to these found by
others, the glucose levels found here are much lower. This may mean
that the individuals under study here are well adapted to starvation,
maximally limiting muscle catabolism and alanine derived
gluconeogenesis, and using only minimal quantities of glucose for
energy. If free fatty acids (FFA) were being preferentially used for
energy production then it might be expected that FFA levels would be
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higher than normal. In fact, only one previous study of alanine
clearance recorded FFA levels (Genuth and Castro 1974) ,and although
they were similar to the levels found here lactate, pyruvate or ketone
body levels were not measured, thus making meaningful comparisons
difficult.
In this study of patients with biliary obstruction and
non-jaundiced control subjects, all of whom were suffering from some
form of malignant disease, no difference was noted in fasting alanine
or glucose levels or in fasting lactate pyruvate or acetoacetate
levels. FFA levels were probably similar but difficulty in measuring
them due to the high bilirubin concentration in the serum of jaundiced
patients made precise comparisons impossible.
However, no definite conclusions about muscle catabolism based
solely on the measurement of fasting levels can be made since a
dynamic equilibrium exists between alanine production from muscle and
hepatic clearance. Alanine clearance studies demonstrated the
relative importance of these two mechanisms.
When compared with the results of others (Elia et al 1980, Royle
and Kettlewell 1981, Swaminathan 1981) the median alanine half life is
greatly increased in this study. Although the range of values for
alanine half-life is very wide in both jaundiced and non-jaundiced
groups no significant difference is seen between these groups. Not
only is there no significant difference between the alanine clearance
rates in jaundiced and non-jaundiced groups, but the clearance rates
in this and other studies are also similar. The apparent difference
between 2 separate methods for examining disappearance of an infused
substrate highlights the difficulty encountered in analysing such
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results..
Since the calculation for clearance rate takes into account
variations in distribution volume and body weight this may imply that
the wide variations found in half life values was as a result of a
wide variation in these parameters. An examination of the body
weights of individuals studied by Elia et al and Royle and Kettlewell
throws doubt on this theory as similar ranges of these parameters were
found in the absence of a wide range of alanine half-lives.
However, it can be assumed that alanine clearance, whether
measured by clearance rate (ml/min/kg) or half life (mins) is either
normal or reduced in comparison to other studies and is unaffected by
the presence of biliary obstruction. Since fasting alanine values are
low in both groups studied here it can be concluded that these low
levels are a result of markedly decreased release of alanine from
muscle. This would suggest that patients who are cachectic as a
result of malignancy may display a reduced catabolic drive. Such a
conclusion is very difficult to accept in view of the frequency with
which cachexia is associated with malignancy.
Jeevanandara et al (1984) notes a lower blood alanine
concentration in cancer patients than in fasted normal subjects
despite a similar or slightly increased alanine flux from the
peripheral muscle. He suggests that this is part of an increased
catabolic drive to make available increased quantities of glucogenic
precursors. This would imply that estimates of the rate of clearance
of unphysiological quantities of alanine from the venous circulation
is valueless as an index of the clearance rate of endogenously
produced alanine. This is a strong argument for the abandoning of
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alanine clearance studies except perhaps where tracer techniques are
used.
After infusion of alanine, the pyruvate, lactate, glucose and
acetoacetate levels varied only slightly and did not appear to deviate
significantly from fasting levels. Royle and Kettlewell noted a fall
in ketone body levels after alanine infusion in septic patients.
Although fasting levels were similar in this study no such change was
noted in response to alanine infusion. No explanation for this can be
proposed.
Changes reported in glucose concentration by Royle and Kettlewell
are tiny and probably not significant. Indeed Fernandes and Blom
(1974) suggest that an overnight fast is not long enough to produce a
significant glucogenic response from alanine administration.
Only minor variations in pyruvate and lactate concentrations were
noted after alanine infusion, none of which reached statistical
significance. The only major change recorded was a dramatic reduction
in FFA concentrations suggesting a significant change in energy
substrate. Since the majority of studies of alanine clearance have
ignored alternative energy sources no comparisons can be drawn. The
presence of biliary obstruction does not affect the rate of FFA
clearance in response to alanine infusion.
In only one report (Elia et al 1980) have patients been studied
who have some degree of liver dysfunction. They reported four
patients with cirrhosis having increased alanine half lives and
decreased clearance rates, thus demonstrating the effect of serious
hepatocellular damage. Fasting alanine levels in these patients were
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norrnal, implying a reduced rate of alanine release from muscle, and,
suggesting there must be a reduced rate of muscle catabolism in the
presence of such reduced clearance. Although the half lives recorded
in the present work are longer than those found in the cirrhotic
patients above, clearance rates are normal. This suggests that the
clearance of alanine in biliary obstruction is more efficient than in
the patient with hepatic cirrhosis.
The main aim of this study was to determine the effect of biliary
obstruction on gluconeogenesis from alanine and on muscle catabolism.
No differences were noted between the jaundiced and non-jaundiced
groups in terms of substrate and metabolite levels before and during
the alanine clearance test. A relative homeostasis obtains and
controlling mechanisms are of secondary importance. After detailed
discussion, therefore, it was considered unnecessary to examine
insulin, glucagon and growth hormone levels although their importance
has been demonstrated in the past (Felig 1973, Royle and Kettlewell
1981).
In the same way that the amount of functioning hepatic tissue can
affect the rate of alanine clearance it might be assumed that the
available quantity of muscle may affect alanine production.
The state of nutrition was recorded in all patients in this
study. Malnutrition varied from a minimal to an advanced degree.
Numerous indices of nutritional status were recorded. As has already
been mentioned, individual indices of nutritional status are of
limited value in determining the degree of malnutrition. This is due
to the serious limitations of the measuring techniques or the limited
application of the result to the whole individual.
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A comparison of techniques to determine whether a predictive
correlation existed between them showed little similarity in results,
a significant association being found only between total body
potassium, serum albumin and thyroxine binding prealbumin, and between
arm muscle circumference and weight loss related to ideal weight, and
forearm muscle circumference and real weight loss. This lack of
similarity between results confirms the poor predictive value of any
single measurement of nutritional status. When ranges of such
measurements are examined alongside the respective fasting alanine
concentration, no association can be found between nutritional status
and such levels. This also holds true for alanine clearance rates and
half lives.
Therefore, apart from the need to record body weight for the
calculation of alanine clearance, no additional value exists in
recording complex parameters of nutritional status. The lack of
association between alanine metabolism and nutritional status throws
doubt on the importance of the equilibrium of the glucose alanine
cycle in muscle catabolism. It may be, as suggested above, that at
the time of study the active phase of catabolism may have passed,
especially in chronic illness such as malignancy.
The study of preoperative fasting levels and clearance rates in
patients with malignancy demonstrates no abnormality attributable to
biliary obstruction. When compared to other studies the fasting
levels found here are very low despite clearance rates being similar
and alanine half lives being prolonged. This suggests that a
controlling mechanism appears to exist which may be peculiar to the
patient with malignancy. Acetoacetate levels are high and this may
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reflect an overall increase in ketone body production which is known
to limit alanine release. Although the anorexia of malignancy may
contribute to this no association could be drawn between nutritional
status and either fasting alanine levels or alanine clearance.
The present study has suffered from having no group comprising
healthy controls but its aim was chiefly to determine the effect of
biliary obstruction on alanine metabolism. Since alanine homeostasis
did not differ between the study and control groups, measuring the
levels of insulin, glucagon and growth hormone would provide results
which would be of little import.
In conclusion, therefore, inasmuch as it can be determined from
this work, it would appear that when considering preoperative
nutritional support for the patient with biliary obstruction no
special formulations are required. Preoperative nutritional support
may improve postoperative prognosis in biliary obstruction, but no
specific abnormalities in the glucose alanine cycle exist to support
this view. It is likely that studies of alanine clearance are either
unable to demonstrate the relevant metabolic changes or are
unassociated with nutritional metabolism in otherwise uncomplicated
biliary obstruction.
5.2.2 A comparison of pre and postoperative alanine clearance.
Of the 20 patients who were studied preoperatively, 4 with
biliary obstruction and 3 with normal liver function were also studied
postoperatively. A comparison of preoperative and postoperative data
shows an apparent 50 percent increase in the rate of alanine clearance
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in the patients with biliary obstruction which is not seen in the
control subjects-
Postoperative alanine clearance studies have been carried out by
3 groups of workers (Royle and Kettlewell 1981, Swaminathan et al 1981
and Elia et al 1980) but in only one study (Elia et al 1980) were the
patients studied both pre and postoperatively. Their results indicate
that the fasting alanine level fell within 6 hours of surgery being
lowest on the second postoperative day. After that it was shown to
return towards normal by the end of the first postoperative week. The
clearance rate was maximal and half life minimal by the third
postoperative day and these too had begun to return to normal by the
7th postoperative day.
In the present study it is considered that such small cohorts
cannot provide conclusive or reliable data despite the use of such
numbers in other studies (Elia et al 1980). Discussion of these data
is therefore limited.
The non-jaundiced group demonstrated a drop in the median fasting
alanine level which is not statistically significant, and the median
half life and median alanine clearance rate did not change. However,
in the group with biliary obstruction there is a significant fall in
the half life and rise in the clearance rate of around 50 percent.
The median fasting levels did not change.
It has already been noted that nutritional status measurements do
not seem to correlate with alanine metabolism and for the most part no
significant change is recorded in the postoperative groups under
study. However, the midarm muscle circumference, showed a significant
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reduction postoperatively. This change is only significant in the
group with biliary obstruction.
Although this change reaches significance in only one parameter
there is a general trend in other parameters towards a more
malnourished state. When this is considered in conjunction with an
increased alanine clearance rate, in the group with biliary
obstruction, an increased rate of muscle catabolism seems likely.
This, therefore, offers further evidence in favour of an aggressive
nutritional support program for the patient recovering from surgery
for biliary obstruction.
5.3.1 The Intravenous Glucose Tolerance Test
Glucose clearance has been studied extensively in many
physiological and pathological situations. Three major pathological
situations were under study here: patients with malignant disease;
patients with malignant obstructive jaundice; and, the same patients
following surgery. Since the first report by Freund (1885) many
authors have remarked on the frequency of glucose intolerance in
malignancy (Friedwald and Grove 1920, Glicksman and Rawson 1956,
Weisenfeld et al 1962, Benjamin and Romney 1964, Marks and Bishop
1957, Jasani et al 1978 and Schein et al 1979).
Although a reduced rate of glucose clearance was noted in some of
the patients under study here, both reduced and increased rates have
been reported in the past in relation to a variety of malignant
processes. Hypoglycaemia has been a reported symptom of
leiomyosarcoma and of hepatocellular carcinoma (Chandalia and Boshell
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1972, Kreisberg and Pennington 1970) and in 1966 Unger reviewed 98
similar cases reported in the literature to that date. However,
impaired glucose tolerance is a much commoner problem, several cases
of which were found in the present study. No case of hypoglycaemia
was encountered.
No patient had a fasting glucose level above normal, but in 11
(55%) the blood glucose failed to return to normal within an hour.
This occurred equally in both groups. Therefore, in the patient with
malignant disease, a fasting blood glucose may mislead the observer
into believing that normal glucose homeostasis exists.
In 1920, Friedenwald and Grove noted 31 of 32 previously reported
cases of gastrointestinal malignancy with high fasting glucose levels
and impaired tolerance to an oral glucose load. Glicksman and Rawson
(1956) found impaired glucose tolerance in 37% of 628 patients with
all types of cancer, and this was also found in 62% of 31 patients
with cancer reported by Weisenfeld et al (1962), and in 56% of 75
patients with endometrial cancer studied by Benjamin and Romney
(1964) .
Decreased glucose tolerance may reflect either diminished
secretion of, or, a diminished response to endogenous insulin. Schein
et al (1979) suggests that a metabolic toxin is released from the
tumour which reduces insulin sensitivity in the individual. However,
Jasani et al (1978) recorded an impaired insulin release, in patients
with malignancy, and noted an association between the severity of
glucose intolerance and the degree of cachexia. The mean clearance
constant (k) was 1.06 (SDK).27) for the cachectic patients, 1.63
(SD=0.23) for the non-cachectic patients with cancer, and 1.64
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(SD=0.34) for the normal subjects. In the present study k values
ranged from 0.15 to 2.24 and 45% (9/20) were within the diabetic
range. No association was found between any measure of nutritional
status and the glucose clearance rates.
Glucose intolerance is also recognised in obstructive jaundice.
Solar et al (1974) examined 23 patients with obstructive jaundice by
means of an oral glucose tolerance test. Of these patients, 12 had
carcinoma of pancreas, 6 gall stone disease, 4 had drug induced
cholestasis and one had hepatitis. Seven of those with carcinoma and
6 of the remainder were shown to have a diabetic response to a glucose
challenge. These data implicate the obstruction rather than the
absolute pathology as the causative factors in glucose intolerance in
obstructive jaundice in contrast to the present findings.
According to the criteria of Lundbaek (1962) it is suggested that
the patients with a glucose clearance constant (k) less than 0.9
(%/min) can be considered diabetic, and those with a k value greater
than 1.05 are normal. Patients with a k value between 0.9 and 1.05
can be considered mildly diabetic.
In the present study, of the group with obstructive jaundice 6
(55%) fell into the diabetic group, 3 (27%) into the non-diabetic
group and 2 (18%) could be considered mildly diabetic. In the control
group, 3 (38%) were diabetic and the remainder, 5 (62%), were
non-diabetic. There is no significant difference between these groups
despite a trend to poorer glucose tolerance in the jaundiced group.
Despite the small numbers in each group it can be assumed that the
presence of obstructive jaundice may not be the sole contributing
factor to the impaired glucose tolerance in this condition, and that
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malignancy must be considered to be an additional factor.
It must also be borne in mind that the results of Solar et al
(1974) were based upon an oral glucose tolerance test. The present
study avoids the influence of altered gastrointestinal absorption
commonly found in obstructive jaundice as well as the complex
endocrine response to intraluminal glucose.
Following partial or complete resolution of jaundice, further
study showed no improvement in glucose clearance. The presence of
biliary obstruction, therefore, did not appear to alter the rate of
glucose clearance. In both groups of patients under study, the
glucose clearance rate was impaired to a similar extent and the
presence of biliary obstruction produced no noticeable deterioration
in this rate. The earlier studies of alanine metabolism can,





Hepatic gluconeogenesis from alanine and the intravenous
clearance of glucose have been studied in patients with malignant
disease, some of whom had biliary obstruction. A comparison of
fasting substrate and metabolite levels, and, substrate clearance
rates were compared in jaundiced and non-jaundiced groups, before and
after surgery. Postoperative studies were conducted after biliary
obstruction had been relieved. This allowed the comparison of paired
data where the only differences were the presence and absence of
obstructive jaundice before and after surgery, respectively.
After an overnight fast, basal alanine levels, alanine clearance
rates and the associated substrate metabolism were similar in both
study and control groups. In the subgroups studied both pre- and
postoperatively no change was noted in the control group, but
clearance rates in the previously jaundiced group increased
significantly by 50 percent. Since this change occurred in the
presence of unchanged fasting alanine levels this implies there is an
increase in the production of muscle-derived alanine. Such a change
is not normally seen in the late postoperative period. In the absence
of adequate nutritional support this could lead to an increased rate
of protein catabolism. Aggressive and prolonged nutritional support
is recommended after surgery for biliary obstruction.
Fasting lactate levels also increased in the postoperative group
recovering from biliary obstruction. The reason for this is uncertain
but may indicate a change to an alternative fuel substrate.
The clearance of an intravenous glucose load was prolonged in
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both groups of patients. In the control group this was, presumably,
as a result of the existing malignant disease. Whereas this may also
be true in the group with biliary obstruction, abnormal hepatic
function was examined as a contributory factor. The postoperative
glucose clearance study demonstrated no change in clearannce rate
suggesting that the presence of biliary obstruction causes no further
deterioration in glucose tolerance in the patient with malignant
disease. These results also demonstrate that no serious alteration to
glucose clearance existed in the patients in whom alanine tolerance
tests were carried out.
FFA levels were recorded to determine the degree of conversion to
FFA as an alternative to carbohydrate as a fuel source. In both the
alanine and glucose clearance tests there was evidence of a conversion
to FFA for energy production in the fasting patient. FFA levels fell
following infusion of both substrates.
It might be assumed that fasting alanine levels and alanine
production might be affected by nutritional status and estimations of
muscle bulk. However, no association was found between nutritional
status and either glucose or alanine metabolism.
5.4.2 Further work
This work represents a small inroad into nutritionally related
metabolic studies in the patient with biliary obstruction. Its
weaknesses lie in the inability to follow, except by inference, the
fate of the various components of the alanine molecule. If further
work of this kind is considered it should employ labelling techniques
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to obtain maximal information. In addition, the study of steady state
environments brought about by constant infusion techniques, would make
interpretation of results easier.
The present study has failed to indicate preoperative
abnormalities in patients with biliary obstruction which might account
for the postoperative morbidity and mortality rates seen in this
condition. Other metabolic parameters should also be investigated. A
study of the rate of clearance of lipid emulsions, would be valuable,
14
and has been planned. By labelling a trioleate molecule with C
14 14
the rate of C 0^ production and the decrease of C -labelled
trioleate would accurately record the drive to lipid metabolism in
these patients.
Aggressive postoperative nutritional support for a prolonged
period should also be considered in patients having surgery for
biliary obstruction. However, even in centres where such patients are
regularly seen the population size of a study and a control cohort
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Preoperative alanine tolerance test
TABLES 6a. Alanine levels (mmol/1) in jaundiced patients
1 2 3 4 5 6 7 8 9 10
0 0.19 0.09 0.16 0.14 0.13 0.16 0.22 0.08 0.07 0.14
10 1.64 1.33 1.83 1.73 1.49 1.74 1.24 1.30 1.62 1.44
20 1.28 1.22 1.61 1.18 1.41 1.33 1.21 0.67 1.13 1.13
TIME 30 0.99 1.05 1.43 0.99 1.03 1.26 0.94 0.77 1.24 0.87
(mins) 40 1.08 0.95 1.37 0.93 0.93 0.95 0.80 0.72 1.11 0.89
50 0.84 0.87 1.37 0.80 0.96 0.73 0.50 0.61 1.05 0.83
60 • 0.53 0.80 0.94 0.75 0.90 0.66 0.51 0.59 0.64 0.60
Slope -.017 •-.010 ■-.014 ■-.011 •-.011 •-.019 ■-.018 -.003 ■-.012 -.011 (mraol/min)
Half life 34.0 82.5 60.0 60.0 78.5 36.0 28.5 145.0 52.0 51.0 (mins)
k 2.04 0.84 1.16 1.16 0.88 1.93 2.43 0.48 1.33 1.36 (%/min)
Y-intercept 1.99 1.34 2.08 1.45 1.52 2.07 1.95 0.81 1.7 1.43 (mmol/1)
Clearance rate 23.61 13.15 10.54 13.94 9.85 19.92 28.85 11.58 15.8 20.32 (ral/mln/Kg)
TABLE 6b. Least squares regression analysis for linearity
Significance
Regression coefficient F1 37.10










Preoperatlve alanine tolerance test
TABLE 7a. Alanine levels (mraol/1) in non-jaundiced patients
1 2 3 4 5 6 7 8 9 10
0 0.16 0.20 0.11 0.29 0.13 0.13 0.11 0.18 - 0.22
10 1.19 1.92 1.86 1.79 1.45 1.92 1.91 1.52 1.27 1.45
20 1.25 1.73 1.45 1.46 1.28 0.77 1.54 1.08 0.92 1.10
TIME 30 0.75 1.39 1.11 1.21 0.96 0.97 1.49 0.94 0.79 1.13
(inins) 40 - 1.05 1.01 1.39 0.61 0.77 1.34 0.94 0.58 1.08
50 0.64 0.44 1.09 1.15 0.68 1.04 1.39 0.74 0.58 0.68
60 . 0.66 1.09 0.88 1.07 0.59 0.98 1.33 0.77 0.50 0.60
Slope -.013 •-.022 ■-.012 •-.008 ■-.017 •-.005 -.005 -.008 --.011 -.015 (mmol/min)
Half life 31.0 29.5 67.5 84.0 38.5 >500 160 75.0 45.0 46.5 (mins)
k 2.24 2.35 1.03 0.83 1.8 0 0.43 0.92 1.54 1.71 (%/min)
Y-intercept 1.95 2.66 1.64 1.63 1.69 0.76 1.63 1.28 1.21 1.77 (mmol/1)
Clearance rate 25.42 20.54 17.91 10.95 20.59 0 8.9 11.53 20.4 20.22 (ml/min/Kg)
i
TABLE 7b. Least squares regression analysis for linearity
Significance
Regression coefficient F1 19.60









TABLE 8a. Summary of preoperative alanine clearance
Biliary Obstruction Control
(Median) (Median)
Fasting levels (mmol/1) 0.135 (0.149) 0.168 (0.184) NS
Slope (mmol/1) -0.011 (0.017) -0.01 (0.018) NS
k (Z/min) 1.22 (1.97) 1.28 (2.35) NS
Half life (min) 56 (116.5) 56.25 (> 130) NS
Clearance (ml/min/Kg) 14.87 (19) 18.03 (25.42) NS
Figures in this table represent median values of ranges. The figures
within brackets denote the extent of each range. Ranges were compared
using the Mann Whitney U test. NS denotes no significance (p > 0.1).
Preoperative alanine tolerance test
TABLE 9a. Glucose levels (mmol/1) in patients with obstructive jaundice
1 2 3 4 5 6 7 8 9 10
0 2.97 3.66 3.76 5.44 5.33 3.50 3.33 4.41 3.50 3.93
10 3.55 4.56 4.18 5.30 4.92 3.61 3.38 5.03 3.42 3.38
20 4.00 4.33 4.32 5.39 6.17 3.71 3.63 5.22 4.01 3.68
TIME 30 4.19 4.58 4.27 5.21 5.56 3.38 3.65 5.00 3.94 3.31
(mins) 40 4.01 4.27 - 5.69 4.02 3.18 3.85 5.24 3.76 3.80
50 3.86 4.09 4.39 5.15 3.79 3.66 3.65 5.38 2.41 4.24
60 . 3.12 4.09 4.68 5.71 3.87 2.86 3.75 4.39 3.67 3.77
SLOPE .004 .001 -.004 .003 -.031 -.008 .007 .002 -.006 .005
(mmol/min)
TABLE 9b. Least squares regression analysis for linearity
Significance
Regression coefficient F1 0.074









Preoperative alanine tolerance test
TABLE 10a. Glucose levels (mmol/1) in non-jaundiced patients
1 2 3 4 5 6 7 8 9 10
0 4.37 5.50 4.79 3.01 3.75 3.22 3.62 5.33 3.59 2.75
10 6.09 4.48 3.34 3.63 4.01 3.98 3.59 5.09 3.98 2.83
20 5.48 5.20 3.80 4.01 3.97 3.24 4.67 4.96 3.92 3.02
TIME 30 5.00 5.39 3.89 3.87 4.03 4.18 5.14 5.25 4.30 3.14
(rains) 40 - 5.52 3.36 4.05 4.04 3.84 4.48 5.02 4.22 3.18
50 6.51 5.50 4.18 3.81 4.09 3.96 4.41 4.22 4.69 3.10
60 . 4.69 5.97 4.20 3.89 4.08 3.01 4.91 4.72 4.46 3.35
SLOPE .006 .013 -.002 .011 .004 0 .019 -.013 .015 .009
(mmol/min)
TABLE 10b. Least squares regression analysis for linearity
Significance
Regression coefficient F1 1.338










TABLE 11a. Preoperative Alanine Tolerance Test
Summary of fasting glucose levels
MEDIAN RANGE N
(mraol/1) (mmol/1)
Bilirubin > 100umol/l 3.635 2.75 10 „
NS
Bilirubin < 100umol/l 3.71 2.47 10
TABLE lib. Preoperative Alanine Tolerance Test
Summary of peak glucose levels
MEDIAN RANGE N
(mmol/1) (mmol/1)
Bilirubin > 100umol/l 4.71 3.16 10
„
NS
Bilirubin < 100umol/l 4.265 2.46 10
■k
Mann Whitney U test.
Preoperative alanine tolerance test
TABLE 12a
Free fatty acid levels (mmol/1) in patients with obstructive jaundice
1 2 3 4 5 6 7 8 9 10
0 0.46 0.89 0.79 1.22 0.91 0.73 0.73 1.32 1.00 0.77
10 0.37 1.09 0.76 1.32 0.83 0.68 0.46 1.13 0.92 0.67
20 0.31 1.08 0.71 1.01 0.53 0.77 0.35 0.93 0.80 0.48
TIME 30 0.17 0.84 0.68 0.86 0.61 0.66 0.31 0.87 0.67 0.52
(mins) 40 0.18 0.83 0.55 0.84 0.46 0.49 0.27 0.83 0.58 0.49
50 . 0.17 0.74 0.64 0.86 0.50 0.40 0.23 0.76 0.66 0.40
60 0.24 0.56 0.63 0.69 0.48 0.32 0.32 0.60 0.59 0.33
SLOPE -.004 -.007 -.003 -.010 -.007 -.007 -.006 -.011 -.007 -.007
(mmol/min)



















Preoperative alanine tolerance test
TABLE 13a
Free fatty acid levels (mrnol/1) in non-jaundiced patients
1 2 3 4 5 6 7 8 9 10
0 0.41 0.44 0.79 0.66 0.50 0.43 0.68 0.97 0.61 0.59
10 0.16 0.42 0.38 0.56 0.38 0.31 0.68 1.03 0.60 0.66
20 0.16 0.39 0.29 0.52 0.34 0.23 0.58 0.95 0.61 0.51
TIME 30 0.11 0.39 0.23 0.36 0.19 0.21 0.50 0.93 0.40 0.63
(mins) AO - 0.36 0.28 0.30 0.15 0.20 0.34 0.68 0.57 0.49
50 • 0.09 0.31 0.20 0.31 0.13 0.20 0.28 0.53 0.62 0.48
60 0.15 0.29 0.22 0.33 0.15 0.17 ,0.25 0.53 0.61 0.51
SLOPE -.003 -.003 -.007 -.006 -.006 -.004 -.008 -.009 0 -.002
(mmol/min)
TABLE 13b Least squares regression analysis for linearity
Significance
Regression coefficient F1 15.307










TABLE 14a. Preoperative Alanine Tolerance Test
Summary of fasting free fatty acid levels
MEDIAN RANGE N
(mmol/1) (mmol/1)
Bilirubin > 100umol/l 0.8 0.86 10 „
pC.Ol
Bilirubin < 100umol/l 0.595 0.56 10
TABLE 14b. Preoperative Alanine Tolerance Test
Summary of free fatty acid clearance rates
MEDIAN RANGE N
(mmol/1) (mmol/1)
Bilirubin > 100umol/l -0.007 0.008 10 *
NS
Bilirubin < 100umol/l -0.007 0.008 10
•k
Mann Whitney U test
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Preoperative alanine tolerance test
TABLE 15a. Lactate levels (mmol/1) in patients with obstructive jaundice
1 2 3 4 5 6 7 8 9 10
0 2.31 1.40 0.68 1.08 0.82 0.92 0.33 0.72 0.27 1.42
10 2.30 1.01 0.72 0.94 0.89 0.96 0.84 - 0.42 1.59
20 2.13 1.16 0.58 1.44 0.86 0.76 0.98 1.20 0.40 1.62
TIME 30 1.60 0.89 1.37 1.07 1.15 0.95 0.89 - 0.58 1.61
(mins) 40 2.22 0.80 0.97 1.17 0.80 0.85 0.60 1.50 0.33 1.22
50 2.31 0.95 0.98 0.81 0.79 0.63 0.87 1.27 0.45 1.28
60 2.02 0.87 1.10 1.18 0.65 0.94 0.84 1.08 0.45 1.20
SLOPE -.003 -.007 .008 0 -.003 -.002 -.004 -.007 -.002 -.006
(mraol/min)











Linearity coefficient F2 0.097
Degrees of VI 5
Freedom V2 61
N.S.
Preoperative alanine tolerance test
TABLE 16a. Lactate levels (mmol/1) in non-jaundiced patients
1 2 3 4 5 6 7 8 9 10
0 0.35 - 1.38 0.79 0.79 0.56 0.82 1.01 0.54 0.99
10 0.47 2.41 1.33 0.73 0.97 0.84 0.74 0.91 0.48 1.03
20 0.49 2.54 1.24 1.00 0.96 0.86 0.34 0.97 0.57 0.84
TIME 30 0.45 2.67 1.45 0.69 1.47 1.00 0.87 1.18 0.78 0.76
(mins) 40 - 2.01 1.40 0.86 1.08 0.80 1.00 .130 2.36 0.73
50 0.40 2.21 1.21 1.04 0.96 1.01 0.87 1.16 1.06 0.62
60 0.52 1.66 0.76 0.84 0.94 1.61 1.13 0.93 0.88 0.53
SLOPE .001 -.015 -.007 .002 .002 .012 .007 .002 .014 -.008
(mmol/rain)
TABLE 16b. Least squares regression analysis for linearity
Significance
Regression coefficient F1 1.02
Degrees of VI 1 N.S.
Freedom V2 61
Linearity coefficient F2 0.691
Degrees of VI 5 N.S.
Freedom V2 61
TABLE 17a. Preoperative Alanine Tolerance Test
Summary of fasting lactate levels
MEDIAN RANGE N
(mmol/1) (mraol/1)
Bilirubin > 100umol/l 0.83 2.04 10




TABLE 17b. Preoperative Alanine Tolerance Test
Summary of peak lactate levels
MEDIAN RANGE N
(mmol/1) (mmol/1)
Bilirubin > 100umol/l 1.38 1.73 10 *
NS
Bilirubin < 100uraol/l 1.185 2.15 10
*
Mann Whitney U test
TABLE 18a.
Preoperative alanine tolerance test
Pyruvate levels (mmol/1) in jaundiced patients
1 2 3 4 5 6 7 8 9 10
0 0.11 0.11 0.12 0.03 0.14 0.06 0.13 0 08 0.03 0.07
10 0.10 0.12 0.12 0.12 0.15 0.08 0.16 0.16 0.03 0.07
20 0.16 0.15 0.12 0.12 0.15 0.09 0.14 0.18 - 0.12
TIME 30 0.13 0.16 0.13 0.12 0.18 0.11 0.16 0.14 0.04 0.04
(mins) 40 0.12 0.15 0.16 0.09 0.12 0.08 0.13 0.17 0.04 0.07
50 0.26 0.12 0.14 0.10 0.13 0.08 0.16 0.15 0.02 0.07
60 0.20 0.11 0.19 0.09 0.15 0.05 0.16 0.08 0.03 0.07
SLOPE .002 0 .001 0 0 0 . 0 0 0 0
(mraol/min)
TABLE 18b. Least squares regression analysis for linearity
Significance
Regression coefficient F1 1.056










TABLE 19a. Pyruvate levels (mmol/1) in non-jaundiced patients
1 2 3 4 5 6 7 8 9 10
0 0.12 0.11 0.10 0.16 0.09 0.06 0.07 0.13 0.08 0.03
10 0.11 0.15 0.12 0.16 0.14 0.07 0.12 0.13 0.10 0.05
20 0.13 0.17 0.18 0.17 0.16 0.07 0 09 0.16 0.12 0.05
TIME 30 0.14 0.18 0.10 0.18 0.14 0.10 0.16 0.15 0.13 0.03
(min8) 40 - 0.17 0.10 0.21 0.16 0.08 0.17 0.18 0.13 0.04
50 0.14 0.17 0.14 0.15 0.14 0.09 0.11 0.16 0.110 0.04
60 0.13 0.21 0.13 0.19 0.15 0.08 0.10 0.15 0.08 0.04
SLOPE 0 .001 0 0 0 0 0 0 0 0
(mraol/min)
TABLE 19b. Least squares regression analysis for linearity
Regression coefficient F1 ' 2.67















TABLE 20a. Preoperative Alanine Tolerance Test
Summary of fasting pyruvate levels
MEDIAN RANGE N
(mraol/1) (mmol/1)
Bilirubin > 100umol/l 0.019 0.302 10
NS
Bilirubin < 100umol/l 0.094 0.125 10
TABLE 20b. Preoperative Alanine Tolerance Test
Summary of peak pyruvate levels
MEDIAN RANGE N
(mmol/1) (mmol/1)
Bilirubin > 100umol/l 0.159 0.216 10
NS
Bilirubin < 100umol/l 0.142 0.158 10
Mann Whitney U test
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Preoperative alanine tolerance test
TABLE 21a.
Aceto-acetate levels (mmol/1) in patients with obstructive jaundice
1 2 3 4 5 6 7 8 9 10
0 0.05 0.09 0.14 0.06 - 0.09 - 0.09 - 0.14
10 0.03 0.10 0.10 0.04 - 0.16 - - - 0.10
20 0.02 0.13 0.11 0.07 - 0.15 - 0.06 - 0.10
TIME 30 0.02 0.09 0.10 0.05 - 0.15 - 0.06 - 0.05
(rains) 40 0 0.09 0.10 0.07 - 0.19 - 0.05 - 0.08
50 0 0.14 0.10 0.05 - 0.16 - 0.05 - 0.11
60 0.14 0.08 0.06 0.06 — 0.15 — 0.07 — ""
SLOPE .001 0 -.001 0 __ .001 0 -.001
(mmol/rain)
TABLE 21b. Least squares regression analysis for linearity
Regression coefficient F1 0.05
Degrees of - VI 1 N.S .
Freedom V2 40
Linearity coefficient F2 0.15
Degrees of VI 5 N.S.
Freedom V2 40
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Preoperative alanine tolerance test
TABLE 22a.
Aceto-acetate levels (mmol/1) In non-jaundiced patients
1 2 3 4 5 6 7 8 9 10
0 0.10 0.05 0.06 - 0.08 0.11 0.05 0.09 - 0.09
10 0.11 0.06 0.04 - 0.05 0.15 0.06 - - 0.10
20 0.11 0.05 0.02 - 0.05 0.11 0.11 0.06 0.12 0.07
TIME 30 0.12 0.07 0.04 - 0.01 0.25 0.12 0.06 0.05 0.09
(rains) 40 - 0.06 0.03 - 0.08 0.17 0.14 0.07 - 0.07
50 0.13 0.06 0.04 - 0.09 - 0.08 0.06 0.08 0.07
60
»
0.11 0.04 0.09 — 0.09 0.12 0.07 0.08 0.07 0.08
SLOPE 0 0 0 0 0
'
.001 0 -.001 0
(mmol/min)
TABLE 22b. Least squares regression analysis for linearity
Significance
Regression coefficient F1 0
Degrees of VI 1 N.S.
Freedom V2 50
Linearity coefficient F2 0.14
Degrees of VI 5 N.S.
Freedom V2 50
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TABLE 23a. Preoperative Alanine Tolerance Test
Summary of fasting aceto-acetate levels
MEDIAN RANGE N
(mraol/1) (mraol/1)
Bilirubin > 100umol/l 0.090 0.092 7 ^
NS
Bilirubin < 100uraol/l 0.087 0.061 8
TABLE 23b. Preoperative Alanine Tolerance Test
Summary of peak aceto-acetate levels
MEDIAN RANGE N
(mmol/1) (mraol/1)
Bilirubin > 100umol/l 0.014 0.117 7 *
NS
Bilirubin < 100uraol/l 0.101 0.194 9
"k
Mann Whitney U test
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Preoperative glucose tolerance test
TABLE 24a. Glucose levels (mmol/1) in patients with obstructive jaundice
1 2 3 4 5 6 7 8 10 11 12
0 3.12 4.02 5.85 5.00 4.08 2.83 5.49 5.73 3.68 3.73 3.93
10 16.00 11.23 10.79 10.61 9.19 9.71 14.15 13.16 9.50 12.67 10.48
20 9.43 10.47 9.73 9.75 7.80 8.68 12.41 10.41 9.99 10.35 8.72
TIME 30 8.45 10.01 8.43 8.89 7.16 7.84 12.00 10.37 8.77 10.49 7 .32
(mins) 40 7.05 8.80 7.17 8.84 6.29 6.33 10.07 9.52 8.25 8.71 6.55
50 7.23 7.87 7.03 6.87 5.50 5.37 10.09 9.73 7.05 7.88 5.96
60 7.02 7.48 6.81 6.57 5.77 5.62 10.00 9.20 6.73 6.68 5.90
SLOPE -.060 -.081 -.072 -.084 -.057 .-.086 -.059 -.031 -.082 -.100 -.070
(mmol/min)
Y-intercept 11.7 12.4 11.5 11.9 9.2 10.8 14.0 10.1 12.0 13.0 10.5
(mmol/1)
Half life 63 80 80 70 88 62 126 186 70 64 73
(rain)
k 1.1 0.87 0.87 0.99 0.79 1.12 0.55 0.37 0.99 1.08 0.95
(%/min)
Clearance 2.24 1.51 1.48 1.50 1.50 2.29 0.94 0.75 1.82 2.03 2.28
(ml/rain/Kg)
TABLE 24b. Least squares regression analysis for linearity
Regression coefficient F1 26.44











Preoperative gluocse tolerance test
TABLE 25a. Glucose levels (mmol/1) in non-jaundiced patients
2 3 4 6 7 8 9 10
0 3.51 3.64 3.81 4.00 3.65 4.49 3.30 3.9110 11.62 10.72 10.95 14.13 - 10.36 11.03 10.5420 10.29 10.60 10.00 13.57 8.50 - 9.05 6.92TIME 30 9.57 10.16 9.38 12.77 - 10.23 8.36 4.77(rains) 40 8.31 11.44 8.47 8.92 6.81 - 7.16 3.27
50 9.26 10.99 7.12 7.81 6.94 8.60 6.58 2.6060 7.10 9.77 5.86 6.22 4.39 7.56 5.69 3.00
SLOPE -.067 -.008 -.105 -.197 -.091 -.088 -.085 -.100(mmol/min)
Y-intercept 12.5 11.2 13.1 20.0 11.7 20.5 11.5 10.5(inmol/1)
Half life 72 310 52 35 41 43 58 33(min)
k 0.96 0.22 1.33 1.98 1.69 1.61 1.19 2.1(%/rain) >
Clearance 1.85 0.59 2.27 3.13 5.0 1.3 1.72 4.32(ml/min/Kg)
















Preoperative glucose tolerance test
TABLE 26 Summary of glucose clearance
Biliary Obstruction
(Median)
Fasting levels (mmol/1) 4.02 (3.02)
Slope (ramol/1) -0.072 (0.069)
k (%/min) 0.91 (0.75)
Half life (rain) 73.0 (124.0)








Figures in this table represent median values of ranges. The figures
within brackets denote the extent of each range. Ranges were compared
using the Mann Whitney U test. NS denotes no significance for p > 0.05.
Preoperative glucose tolerance test
TABLE 27a.
Free fatty acid levels (mmol/1) in patients with obstructive jaundice
1 2 3 4 5 6 7 8 10 11 12
0 0.69 0.60 0.70 1.52 0.95 0.59 0.80 0.61 0.44 0.26 0.50
10 0.60 0.76 0.63 1.15 0.92 0.66 0.76 0.53 0.43 0.16 0.56
20 0.60 0.70 0.56 0.72 0.86 0.44 0.64 0.41 0.38 0.15 0.66
TIME 30 0.53 0.61 0.72 0.78 0.60 0.31 0.36 0.36 0.32 0.15 0.58
(mins) 40 0.40 0.62 0.46 0.78 0.53 0.25 0.38 0.26 0.26 0.17 0.51
50 0.28 0.55 0.54 0.49 0.51 0.24 0.38 0.30 0.24 0.21 0.43
60 0.30 0.63 0.65 0.75 0.46 0.02 0.28 0.20 0.21 0.24 0.46
SLOPE -.007 -.001 -.002 -.013 -.009 -.008 -.009 -.007 -.004 0 -.002
(mmol/rain)
TABLE 27b. Least squares regression analysis for linearity
Significance
Regression coefficient F1 19.88









Preoperative glucose tolerance test
TABLE 28a. Free fatty acid levels (mraol/1) in non-jaundiced patients
2 3 4 6 7 8 9 10
0 ' 0.32 0.84 1.00 0.30 0.36 0.51 0.31 0.49
10 0.60 1.11 0.74 0.20 0.24 0.55 0.39 0.17
20 0.39 0.41 0.40 0.18 0.20 0.46 0.27 0.13
TIME 30 0.28 0.12 0.30 0.15 - 0.38 0.24 0.15
(rains) 40 0.24 0.22 0.31 0.15 0.19 0.29 0.18 0.15
50 0.18 0.15 0.27 0.15 0.14 0.29 0.20 0.16
60 0.15 0.15 0.41 0.13 0.13 0.23 0.17 0.14
SLOPE -.005 -.014 -.010 -.002 -.003 -.005 -.003 -.004
(mraol/inin)
TABLE 28b. Least squares regression analysis for linearity
Significance
Regression coefficient F1 26.18
Degrees of VI 1 p < .05
Freedom V2 48
Linearity coefficient F2 1.02
Degrees of VI 5 N.S.
Freedom V2 48
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TABLE 29a. Preoperative Glucose Tolerance Test
Summary of fasting free fatty acid levels
MEDIAN RANGE N
(mraol/1) (mmol/1)
Bilirubin > 100umol/l 0.610 1.26 11
Bilirubin < 100umol/l 0.365 0.7 8
NS
TABLE 29b. Preoperative Glucose Tolerance Test
Summary of free fatty acid clearance rates
Bilirubin > 100umol/l
Bilirubin < 100umol/l






Postoperative alanine tolerance test
TIME
(mins)
TABLE 30a. Alanine levels (mraol/1)
Jaundiced Non-jaundiced
4 5 8 9 median 6 9 10
0 0.28 0.25 0.10 0.13 0.19 0.14 0.14 0.09
10 1.31 1.65 1.02 1.28 1.40 1.46 1.18
20 1.13 1.31 0.96 1.17 1.50 1.37 0.99
30 0.98 1.07 0.68 1.07 1.36 1.17 0.86
40 0.84 0.82 0.76 0.87 1.26 1.03 0.74
50 . 0.66 0.73 0.61 0.74 0.85 0.89 0.63
60 0.62 0.67 0.48 0.72 0.96 0.77 0.54
median
0.11
Y-intercept 1.56 1.81 1.23 1.54 1.55 2.01 1.81 1.36 1.81
(mmol/1)
Slope -.010 -.012 -.013 -.017 -.0125 -.016 -.015 -.011 -.015
(mraol/min)
Half Life 44 38 47 51.5 45.5 49 49 45 47.7
(rain)
k 1.58 1.82 1.47 1.35 1.535 1.41 1.41 1.54 1.453
(%/rain)
Clearance 17.67 17.1 23.52 18.69 21.52 12.52 23.68
(ml/rain/Kg)
TABLE 30b. Least squares regression analysis for linearity
Jaundiced Non-jaundiced
Significance Significance
Regression coefficient F1 64.41 15.49
Degrees of VI 1 p < .05 1 p < .05
Freedom V2 21 14
Linearity coefficient F2 0.329 0.10
Degrees of VI 5 N.S. 5 N.S.
Freedom V2 21 14
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TABLE 30c
Comparison of preoperative and postoperative alanine clearance




0.11 (0.07) 0.19 (0.18) n.s. (mmol/1)
-0.011 (0.017) -0.013 (0.007) n.s. (mmol/min)
1.02 (0.85) 1.53 (0.47) p < 0.02 (Z/rain)
Half life 69.25 (93) 45.5 (13.5) p < 0.02 (min)
Clearance 12.76 (5.95) 18.18 (6.42) p < 0.02 (ml/rain/Kg)
All p values greater than 0.05 are not considered significant. For values
less than 0.1 the actual value is listed.
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Table 30d
Comparison Of preoperative and postoperative alanine clearance












0.12 (0.05) n.s. (mmol/1)
-0.015 (0.029) p < 0.03 (mmol/min)
1.44 (0.13) n.s. (Z/tnin)
48 (4) n.s. (rain)
21.52 (11.16) p < 0.06 (ml/min/Kg)
All p values greater than 0.05 are not considered significant. For values
less than 0.1 the actual value is listed.
Postoperative alanine tolerance test
TABLE 31a. Glucose levels (nmol/1)
Jaundiced
4 5 8 9 6 9 10
0 4.11 4.31 3.64 4.49 3.51 3.53 3.38
10 4.18 4.42 3.44 4.48 3.65 4.10 3.40
20 5.92 4.78 3.70 4.68 3.91 3.64 3.60
TIME 30 4.61 5.27 4.06 4.68 4.02 4.30 3.83
(inins) 40 5.57 4.17 4.25 4.89 4.06 4.36 3.74
50 5.03 5.07 3.88 4.81 4.33 4.26 3.57
60 5.22 5.04 4.32 4.46 3.73 4.08 3.57
SLOPE
(mmol/inin)
.017 .010 .012 .003 .009 .009 .004
TABLE 31b. Least squares regression analysis for linearity
Jaundiced Non-jaundiced
Significance Significance
Regression coefficient F1 3.70 5.22
Degrees of VI 1 N.S. 1 N.S.
Freedom V2 21 14
Linearity coefficient F2 0.45 1.23
Degrees of VI 5 N.S. 5 N.S.
Freedom V2 21 14
Postoperative alanine tolerance test
TABLE 32a. Free fatty acid levels (mmol/1)
Jaundiced Non-■jaundiced
A 5 8 9 6 9 10
0 1 .OA 0.97 0.71 0.90 0.A9 0.38 0.60
10 0.75 0.90 0.70 0.85 0.A0 0.A1 0.5A
20 0.58 0.68 0.60 0.66 0.30 0.27 0.25
TIME 30 0.A9 0.69 0.50 0.68 0.26 0.2A 0.19
(mins) AO 0.35 0.57 0.A6 0.53 0.20 0.17 0.39
50 0.35 0.5A 0.53 0.A3 0.18 0.18 0.13
60 0.37 0.51 0.37 0.AA 0.16 0.15 0.16
SLOPE -.005 -.008 -.011 -.008 -.00A -.007 -.005
(mraol/min)





Regression coefficient F1 79.98 5A.05
Degrees of VI 1 p < .05 1 p <
Freedom V2 21 1A
Linearity coefficient F2 1.17 1.66
Degrees of VI 5 N.S. 5 N.S.
Freedom V2 21 1A
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Postoperative alanine tolerance test
TABLE 33a. Lactate levels (mmol/1)
Jaundiced Non-jaundiced
4 5 8 9 6 9 10
0 0.96 0.64 1.64 1.02 0.37 0.96 0.88
10 1.25 0.71 1.54 0.95 0.76 0.89 1.04
20 1.49 1.23 1.49 0.99 0.59 1.23 1.01
TIME 30 1.24 0.85 1.54 1.19 0.78 1.17 0.89
(rains) 40 1.41 0.89 1.10 0.95 0.74 1.05 0.81
50 1.15 0.83 1.23 0.84 0.93 0.88 0.68
60 1.15 0.88 1.59 0.74 0.94 0.90 0.55
SLOPE -.004 -.004 .001 .002 -.001 -.007 .008
(minol/rain) .
TABLE 33b. Least squares regression analysis for linearity
Jaundiced Non-jaundiced
Significance Significance
Regression coefficient F1 0.17 0
Degrees of VI 1 N.S. 1 N.S.











Postoperative alanine tolerance test










TABLE 34b. Least squares regression analysis for linearity
Jaundiced Non-jaundiced
Significance Signific
Regression coefficient F1 0 0.73
Degrees of VI 1 N.S. 1 N.S.
Freedom V2 21 14
Linearity coefficient F2 0.70 0.66
Degrees of VI 5 N.S. 5 N.S.
Freedom V2 21 14
Jaundiced Non-jaundiced
4 5 8 9 6 9 10
0.14 0.07 0.07 0.07 0.09 0.06 0.03
0.22 0.16 0.06 0.12 0.04 0.08 0.06
0.18 0.17 0.06 0.11 0.07 0.07 0.06
0.15 0.17 0.08 0.11 0.07 0.08 0.09
0.17 0.11 0.06 0.10 0.06 0.09 0.08
0.19 0.12 0.10 0.09 0.06 0.09 0.06
0.16 0.10 0.05 0.10 0.06 0.07 0.05
0 0 0 0 0 *0 0
Postoperative alanine tolerance test
TABLE 35a. Acetoacetate levels (mmol/1)
Jaundiced
(mraol/min)
4 5 8 9 6 9 10
0 0.06 _ - 0.08 - 0.05 0.07
10 0.07 - - 0.08 - 0.12 0.11
20 0.07 - - 0.11 - 0.13 0.06
TIME 30 0.06 - - 0.09 - 0.10 0.06
(mins) 40 0.06 - - 0.08 - 0.11 0.06
50 0.07 - - 0.06 - 0.11 0.07
60 0.07 — — 0.07 — 0.11 0.08
SLOPE 0 0 .001 0
TABLE 35b. Least squares regression analysis for linearity
Jaundiced
Significance
Regression coefficient F1 0.174
















Postoperative glucose tolerance test
TABLE 36a. Glucose levels (mmol/1)
Jaundiced
4 5 8 11 9
0 4.65 4.57 3.33 4.77 4.55
10 11.57 9.27 9.28 12.31 10.73
20 8.78 9.26 8.30 13.76 9.23
TIME 30 8.54 8.92 8.18 12.88 8.73
(mins) 40 7.82 7.22 7.92 10.82 7.55
50 7.37 - 7.84 10.33 7.55
















TABLE 36b. Least squares regression analysis for linearity
Jaundiced
Significance
Regression coefficient F1 6.29
Degrees of VI 1 p < .05
Freedom V2 20
Linearity coefficient F2 0.086




Comparison of preoperative and postoperative glucose clearance






4.61 (1.46) n.s. (mmol/1)
-0.044 (0.069) n.s. (mmol/min)
0.85 (0.93) 0.96 (0.78) n.s. (Z/min)
Half life 84 (108) 72.5 (116.5) n.s. (min)
Clearance 1.33 (0.91) 1.56 (1.31) n.s. (ml/min/Kg)
All p values greater than 0.05 are not considered significant. For values
less than 0.1 the actual value is listed.
Postoperative glucose tolerance test
TABLE 37a. FFA levels (ramol/1)
Jaundiced Non-jaundiced
4 5 8 11 9
0 1.26 0.52 0.72 0.59 0.42
10 1.00 0.53 0.89 0.58 0.34
20 0.90 0.46 0.56 0.36 0.38
TIME 30 0.52 0.39 0.66 0.35 0.27
(tnins) 40 0.43 0.40 0.65 0.18 0.27
50 0.42 - 0.59 0.15 0.26
60 0.45 0.41 0.66 0.14 0.23
SLOPE -.015 -.013 -.002 -.009 -.003
(inraol/min) •
TABLE 37b. Least squares regression analysis for linearity
Jaundiced
Significance
Regression coefficient F1 9.76
Degrees of VI L p < .05
Freedom V2 20
Linearity coefficient F2 0.31
Degrees of VI 5 N.S.
Freedom V2 20
TABLE 38. Preoperative Anthropometric Measurements
WT WT LOSS WT/HT MAMC GS LBM
Kg % % % % Kg
1 57.7 4.0 115 105 96 39
2 63.4 13.6 115 91 90 40
3 70.1 9.0 116 98 92 48
Jaundic ed 4 76.0 10.0 109 95 82 55
5 78.4 8.0 119 115 115 62
Patients 6 62.1 6.0 121 95 112 43
7 57.5 11.0 87 90 82 48
8 67.8 17.0 103 95 70 49
9 66.0 13.0 100 95 75 48
10 62.2 14.0 114 92 65 40
11 56.4 4.0 113 98 76 38
12 54.5 -7.0 118 85 25 37
MEDIAN 62.8 9.3 114.5 95 82 43.5
RANGE 23.9 24 34 30 90 25
1 60.0 17.0 99 102 62 47
2 57.2 15.0 94 82 92 48
3 46.5 18.0 77 75 70 46
Ion-jaundiced 4 61.5 15.0 101 91 100 49
5 58.8 18.0 97 79 35 51
Patients 6 43.5 8.0 92 86 90 33
7 39.7 0 86 82 80 25
8 83.3 -1.0 120 101 102 56
9 83.0 -1.0 112 90 101 65
10 63.6 13.00 81 89 80 54
MEDIAN 59.4 13.5 94.5 86.5 80.5 48.5
RANGE 21.8 19 43 27 67 40
n. s. n. s ■ n. s. n• s• n• s• n• s•
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TABLE 39. Preoperative Biochemical Nutritional Parameters
ALB TBK TFN TBPA
1 33 93 1.55 0.07
2 31 91 2.30 0.12
3 25 81 - 0.04
Jaundiced 4 33 83 2.20 0.09
5 41 98 2.55 0.16
Patients 6 34 100 - 0.09
7 33 91 2.85 0.17
8 28 81 1.55 0.06
9 40 89 2.75 0.08
10 29 104 2.05 0.10
11 35 90 2.70 0.22
12 17 - 1.50 0.06
MEDIAN 33 90 3.25 0.09
RANGE 24 23 1.3 0.18
1 30 - - 0.13
2 30 - 3.20 0.07
3 40 - 2.40 0.17
Non-jaundiced 4 42 - 1.90 0.04
5 27 - 1.85 0.06
Patients 6 38 - 2.80 0.23
7 42 - 2.50 0.16
8 40 - 3.55 0.25
9 33 - 2.10 0.17
10 47 - 2.30 0.24
MEDIAN 39 - 2.4 0.165
RANGE 20 - 1.7 0.21
n. s. n. s. n. s.
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TABLE 40. Preoperative Parameters of Renal Function
BUN Se.Cr. Ur.Urea CrCl
1 3.7 74 180 _
2 3.9 81 135 60.0
3 7.8 102 375 71.5
Jaundiced 4 8.3 120 435 91.0
5 4.5 89 498 -
Patients 6 5.0 103 375 62.0
7 5.8 78 235 63.2
8 3.9 60 340 133.2
9 4.1 81 220 49.0
10 2.0 72 110 120.2
11 4.7 69 255 88.6
12 7.1 159 56 12.2
MEDIAN 4.6 81 252 67.4
RANGE 6.3 99 442 121
1 4.5 126 205 46.3
2 7.9 126 - -
3 13.9 83 - -
^on-jaundiced 4 4.9 77 - -
5 7.0 94 390 66.5
Patients 6 4.2 69 229 120.0
7 10.2 57 - -
8 4.4 91 - -
9 7.0 165 - -
10 10.1 68 310 173.6
MEDIAN 7.0 87 269.5 93
RANGE 9.7 108 185 108.:
n. s. n. s. n. s. n. s
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3.5 - 7.8 mmol/1
0.03 - 0.18 mmol/1
0.03 - 0.11 mmol/1
0.45 - 1.55 mmol/1
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